Fish Oil

Fish oil is a general health supplement, and is taken as a source of omega-3 fats. It is not needed if one eats enough fatty fish.

This page features 725 unique references to scientific papers.


Confused about what actually Works?
MUST GET: Supplement Stack Guides - Saving You Money & Time

   

Fish oil is a common term used to refer to two kinds of omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These omega-3 fats are usually found in fish, animal products and phytoplankton. Fish oil is recommended as a source of these omega-3 fats as they are the cheapest and most common source of them.

Fish oil provides a variety of benefits when supplemented, particularly when the ratio of omega-3 and omega-6 fatty acids in the body is almost equal (1:1). The average diet (red meat, eggs, and so forth) are high in omega-6 fatty acids, which is why fish oil is recommended (to balance the ratio).

A ratio of roughly 1:1 is associated with healthier blood vessels, a lower lipid count and a reduced risk for plaque buildup. Fish oil can also decrease the risk of diabetes and several forms of cancer, including breast cancer.

Fish oil works primarily through eicosanoids, which are signalling molecules. A proper ratio of omega 3:6 fatty acids will influence which eicosanoids are released in response to stress.

It should be noted that fish oil can also reduce triglycerides in people with high triglyceride levels. However, it can also increase cholesterol, so care should be taken before supplementing fish oil for this purpose.

Follow this Page for updates

Confused about Supplements?
Get the Stack Guides

Also Known As

Eicosapentaenoic Acid, EPA, Docosahexaenoic Acid, DHA, Omega-3 fatty acids, Omega-3, Omega 3, N-3 Fatty Acids


Do Not Confuse With

Alpha-Linolenic Acid (the plant-based omega-3)


Things to Note

  • Though fish oil is not a stimulant, it increases brain activity, so a stimulatory effect may be felt after supplementation

  • Most of fish oil's beneficial effects happen over a period of days and weeks, rather than immediately

  • Post-supplementation "fish burps" can be avoided by consuming fish oil with food, or freezing the capsules before supplementation

Is a Form of


Goes Well With


Stacks Part Of increased usefulness


Does Not Go Well With

  • Fat-blockers
  • Omega-6 fatty acids, like linoleic acid and arachidonic acid

Caution Notice

  • Fish oil can oxidize if left out in the sun or in heat. Though generally not harmful, it is prudent to refrigerate fish oil.

  • Fish oil can reduce blood clotting and should be supplemented with caution if blood-thinning medications, asprin, warfarin or clopidogrel are already present in the body.

Examine.com Medical Disclaimer

Fish oil doses vary depending on the goal of supplementation. For general health, 250mg is the minimum dose. The American Heart Association recommends 1g daily. If the goal of supplementation is to reduce soreness, a 6g dose, spread over the course of a day, will be effective.

Since fish oil is a combination of two different fatty acids, these numbers reflect a combined total. Total eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) consumption should come from a mix of real food and supplements. The more EPA and DHA is provided by the diet, the less supplementation is required.

Fish oil can be taken throughout the day. To minimize the "fish burp" taste, take fish oil with meals.

Pregnant women should increase their intake of DHA by at least 200mg a day, as long as there is no risk of elevated mercury levels.


I find that fish oil helps combat muscle soreness (DOMS).


Sol Orwell

Right, so I would imagine that supplementing Uridine alongside fish oil would be ideal for anything related to neurology. This is speculation mind you, hence why the other sections of the page don't outright claim they go well together.

The most important sections of this article for overall understanding and comprehension would be the eicosanoid section (how fish oil actually does stuff), the nutrient-nutrient interactions (for synergism), and immunology (fish oil is pretty complex, and isn't just immunosuppressive)


Kurtis Frank

The Human Effect Matrix looks at human studies (excluding animal/petri-dish studies) to tell you what effect Fish Oil has in your body, and how strong these effects are.
GradeLevel of Evidence
ARobust research conducted with repeated double blind clinical trials
BMultiple studies where at least two are double-blind and placebo controlled
CSingle double blind study or multiple cohort studies
DUncontrolled or observational studies only
Level of Evidence
EffectChange
Magnitude of Effect Size
Scientific ConsensusComments
AC-Reactive Protein

Although some decreases have been noted, the vast majority of the evidence suggests that there is no significant influence

ABlood Pressure

Minor

May decrease blood pressure in persons with high blood pressure, but does not appear to have efficacy in persons with normal blood pressure

AInflammation

Minor

Highly mixed and unreliable influences on circulating inflammatory cytokines (although, due to immunosuppression on cellular adhesion factors, the overall effect may still... show

ALDL-C

Minor

A decrease has been noted in persons without high cholesterol in the first place, and the decreasing effect of statins appears to be augmented with fish oil. However, in... show

AHDL-C

Minor

Mixed evidence, but a possible increase in HDL-C is seen with fish oil supplementation in unhealthy persons

ATotal Cholesterol

Although some decreases have been noted, overall there does not appear to be a significant clinical reduction in total cholesterol like there is with triglycerides

ATriglycerides

Strong

Fish oil, both EPA and DHA, are reference drugs for the purpose of reducing triglycerides with highly reliable reductions in the range of 15-30% (higher reductions seen... show

AADHD in Children

Minor

Supplemental DHA above 300mg appears to be effective in reducing ADHD symptoms in children when supplemented

ADepression

Notable

Fish oil supplementation has been noted to be comparable to pharmaceutical drugs (fluoxetine) in majorly depressed persons, but this may be the only cohort that experiences... show

AWeight

For the most part, no significant influence on body weight over time

ABlood Glucose

No significant alterations in fasting glucose are seen over time with fish oil supplementation

AHbA1c

Although the majority of evidence suggests absolutely no influence on HbA1c, reductions have been reported and a lone case has noted a clinically irrelevant increase of... show

AInsulin Sensitivity

No significant influence on insulin sensitivity seems to be the consensus, although there are isolated reports of both an increase and decrease (in response to a glucose... show

BMuscle Soreness

Although one study suggests a decrease, most evidence suggest no significant influence

BTNF-Alpha

Minor

May decrease TNF-a

BVO2 Max

There is no evidence to support an improvement of VO2 max when fish oil is consumed alongside an exercise routine

BCell Adhesion Factors

Minor

Appears to be able to reduce cellular adhesion factors (that draw immune cells into tissue to aid in inflammatory processes, reducing these is immunosuppressive) in elderly... show

BCortisol

Minor

A possible reducing effect of fish oil supplementation on cortisol

BEndothelial Function

Minor

There appears to be a slight increase in vascular reactivity and blood vessel responsiveness that may be independent of both blood flow alterations and blood pressure

BPlatelet Aggregation

Minor

Possible decreases in platelet aggregation

BInsulin

No significant influence on fasting insulin levels

BvLDL-C

Minor

May decrease vLDL cholesterol

BApolipoprotein B

Although at least one study has noted a decrease, usually there is no significant changes

BBlood Flow

Although there is some counter evidence to suggest an improvement of small magnitude, most evidence suggest no significant changes in blood flow

BLipid Peroxidation

Minor

Both increases and decreases in lipid peroxidation have been noted with fish oil supplementation, with the increases in peroxidation usually seen with high doses of fish... show

BNatural Killer Cell Content

Although one increase in NK cell content has been noted after exercise, the two studies using similar doses at rest have failed to find a significant influence on NK cell content

BT Cell Count

Although there is some evidence to suggest an immunosuppressive effect on T cells, most evidence suggest no significant effect. When the immunosuppresion does occur, it... show

BB cell count

The overall quantity of B lymphocytes does not appear to be altered with fish oil supplementation

BNatural Killer Cell Activity

Minor

Although there do not appear to be changes in the amounts of NK cells in the body following fish oil, their activity appears to be a tad reduced

BPre-Eclampsia Risk

There does not appear to be a significant protective effect against pre-eclampsia in women who supplement fish oil during pregnancy

BInfant Birth Weight

Minor

There appears to be an increased infant birth weight in mothers that consume fish oil (or fish weekly) relative to no fish oil intake, which may be due to prolonging pregancy... show

BPostpartum Depression

There does not appear to be any unique effect of supplemental fish oil on postpartum depression. Fish oil in postpartum and perinatal periods follows the same motifs as... show

BPhotoprotection

Minor

There appears to be reduced risk of DNA damage, immunosuppression, and erythema in response to sunlight associated with fish oil consumption. Studies have only investigated... show

BSymptoms of Bipolar Disorder

Minor

There appears to be reduced depressive symptoms in bipolar disorder when the depression is of a large magnitude (similar to the anti-depressant effects of fish oil in general).... show

BInsulin Secretion

There does not appear to be an augmented insulin release from dietary carbohydrate nor an inherent insulin release from the pancreas associated with fish oil supplementation

BSymptoms of Systemic Lupus Erythematosus

Notable

The decrease in symptoms of lupus as assessed by SLAM-R and BILAG at times reaches up to 50% symptom reduction and tends to exceed 30%, and the first pilot studies noted... show

CMuscle Damage

No significant influence on biomarkers of muscle damage seen with fish oil supplementation

CHeart Rate

No significant acute effect on heart rate seen with fish oil supplementation

CInterleukin 2

Minor

Mixed effects on IL-2 concentrations, with an increase noted when supplemented around exercise and no change noted at rest.

CInterleukin 5

No significant influence on circulating IL-5 concentrations

CInterleukin 1-beta

No significant influence on circulating IL-1β concentrations

CLeptin

No significant influence on Leptin in serum

CAdiponectin

No significant influence on Adiponectin concentrations

CTestosterone

No detectable influence on testosterone levels in serum

CSex Hormone Binding Globulin

No significant influence on SHBG levels

CDHEA

No significant influence on DHEA sulfate in serum

CLiver Fat

Minor

A possible decreasing effect of liver fat seen in persons with NAFLD

CLiver Enzymes

No significant influence on liver enzymes noted

CApolipoprotein A

No significant influence on Apolipoprotein A concentrations

CGeneral Oxidation

Minor

May increase general oxidation in the body, but seems unreliable in doing so

CNitric Oxide

Minor

An increase in exercise-induced nitric oxide production has been noted

CExercise-Induced Oxidation

Minor

Exercise induced oxidation has been noted to be increased in elite athletes with fish oil supplementation

CDNA Damage

Does not appear to influence DNA damage

COxidation of LDL

No significant influence detected

CHomocysteine

Minor

May decrease homocysteine content

CLymphocyte Count

Minor

A decrease in lymphocytic count has been noted in obese persons

CAnxiety

Minor

A decrease in anxiety has been noted in medical students

CMemory

Minor

Possible improvements in memory

CExercise-Induced Immune Suppression

Does not appear to augment nor alleviate the immunosuppression that occurs during exercise in otherwise healthy persons

CFood Intake

There does not appear to be a significant influence of fish oil supplementation on food intake

CFat Mass

No significant influence on fat mass with routine supplemental fish oil

CLean Mass

No significant influence on lean mass associated with fish oil supplementation

CKetone Bodies

Minor

An increase in ketone bodies has been noted when fish oil is paired with a weight loss diet (relative to placebo)

CSubjective Well-Being

Minor

An improvement in well being has been noted in nondepressed and nonelderly obese persons given fish oil supplementation to a small magnitude.

CInterleukin 6

Minor

A decrease in circulating IL-6 has been noted with fish oil supplementation

CInfant Death Risk

Minor

A reduced risk of death of infants after pregnancy has been noted with maternal consumption of fish oil, but this information is preliminary and needs replication (noted... show

CCognition of Offspring

Despite the importance of DHA in cognition of offspring (and absolute deprivation likely to reduce cognitive development), additional supplemental fish oil does not appear... show

CLeukotriene B4

No significant influence on LKB4 concentrations

CLeukotriene B5

Minor

An increase in LKB5 has been noted following fish oil supplementation

C5-HETE

5-HETE is a catabolite of arachidonic acid (omega-6 fatty acids), and its serum levels do not appear to be significantly influenced by ingestion of fish oil supplementation... show

C5-HEPE

Notable

5-HEPE is a catabolite of EPA, and its blood levels are increased following consumption of EPA in a dose-dependent manner

CErythema

Minor

Ingestion of fish oil appears to prolong the time required for sunlight to induce reddening of the skin, and secondary to this fish oil ingestion above 1,800mg EPA is able... show

CCognitive Decline

Minor

High dose (900mg) DHA appears to be somewhat beneficial in reducing the rate of cognitive decline in elderly but otherwise healthy persons

CSymptoms of Alzheimers

Despite the benefit seen with high dose DHA in cognitive decline, there does not appear to be a proven significant protective effect in persons already with Alzheimer's

CStress

Minor

Self-reported stress in distressed women given fish oil supplementation appears to be reduced

CFatigue

No demonstrable benefit to fatigue

CFructosamine

No evidence to support an increase in fructosamine, which alongside HbA1c is thought to indicate pathology from elevated blood glucose (fish oil appears to elevate glucose,... show

CPlasminogen Inhibitor 1

Minor

An increase in PAI-1 is noted with fish oil supplementation

CGlucagon

No significant influence on plasma glucagon concentrations

CFactor VII

Minor

An increase in serum Factor VII has been noted with fish oil supplementation

CProstaglandin J2a

Minor

An increase in prostaglandin J2A is noted with fish oil supplementation, which is thought to mediate a variety of fish oil's effects

CThromboxane B2

Minor

An increase in thromboxane B2 is noted with fish oil supplementation

CProteinuria

Although a trend to reduce protein losses in the urine was noted (which would be kidney protective), this was a statistically insignificant and secondary to lupus treatment

CAttention

Fish oil supplementation in otherwise healthy adults has failed to significantly influence attention processing

CAggression

Minor

A decrease in aggression has been noted, which is thought to be secondary to improvements in mood state and general well being

CProcessing Accuracy

Minor

An improvement in processing accuracy (assessed by amount of errors in a cognitive test) has been noted with fish oil in otherwise healthy adults that do not frequently... show

CReaction Time

Minor

A reduction in reaction time has been noted with fish oil supplementation in persons who consume low levels of fish in the diet

CCerebral Blood Flow

Minor

Appears to improve cerebral blood flow and volume in persons with low dietary fish intake

CCerebral Oxygenation

Minor

The increase in cerebral oxygenation appears to exist in otherwise healthy persons with low dietary fish intake, and appears to be secondary to improvements in blood flow... show

DMetabolic Rate

No significant influence on metabolic rate seen with fish oil supplementation

DFat Oxidation

Minor

An increase in fat oxidation (percentage of energy being taken from fat tissue) has been noted with fish oil supplementation

DBone Mineral Density

No significant influence on bone mineral density noted with fish oil supplementation


Studies Excluded from Consideration

  • Confounded with other fatty acids[1]

Disagree? Join the Fish Oil Discussion

Table of Contents:

  1. Sources and Active Molecules
    1. Fish oil contents and sources
    2. Structures and Properties
    3. Supplemental sources of Omega-3 fatty acids
    4. DHA deficiency and Regulation of DHA
  2. Eicosanoids (How Fish Oil Works)
    1. Bioactivation of Eicosanoids
    2. Resolvins
    3. Protectins
    4. Prostaglandins
  3. Molecular Targets
    1. PPAR Receptors
    2. AMPK
    3. FFA receptors
  4. Pharmacology
    1. Absorption
    2. Bodily stores
  5. Neurology
    1. DHA concentrations
    2. Aggression
    3. Memory and Learning
    4. Depression
    5. Bipolar Disorder
    6. Stress
    7. Glucose Metabolism
    8. Blood Flow and Oxygenation
    9. Stroke
    10. Dementia and Alzheimer's
    11. Pain
  6. Cardiovascular Health
    1. Mechanisms
    2. Triglycerides
    3. Lipoproteins
    4. Cardiovascular Disease Risk
    5. Endothelial Interactions
  7. Interactions with Glucose Metabolism
    1. Blood Sugar and Glycemic Control
    2. Insulin Sensitivity
    3. Diabetes Risk
  8. Fat Mass and Obesity
    1. Mechanisms
    2. Adipokines
    3. Interactions with Carbohydrates
    4. Weight Gain
    5. Skeletal Muscle Interactions
    6. Interventions
  9. Muscle Mass and Hypertrophy
    1. Mechanisms
    2. Muscle Bioenergetics
    3. Healing rate and Catabolism
    4. Health Effects
  10. Immunology and Inflammation
    1. Circulating Cytokines
    2. Chemotaxis and Cell Adhesion Factors
    3. Neutrophils
    4. Monocytes and Macrophages
    5. Natural Killer Cells
    6. B-Cells
    7. T Cells
  11. Interactions with Oxidation
    1. Lipid Peroxidation
    2. Antioxidant Enzymes
  12. Exercise and Performance
    1. VO2 Max and Oxygen Consumption
    2. Exercise-related Immune Suppression
  13. Pregnancy and Lactation
    1. Benefits to Mothers
    2. Birth
    3. Pregnancy Consumption and Benefit to Offspring
    4. Lactation
  14. Interactions with Organ Systems
    1. Eyes
    2. Pancreas
    3. Kidneys
  15. Interactions with Cancer Metabolism
    1. Skin
    2. Pancreas
  16. Interactions with Disease States
    1. Lupus erythematosus
  17. Interactions with Aesthetics
    1. Skin
    2. Hair
  18. Nutrient-Nutrient Interactions
    1. Uridine
    2. Linoleic Acid (Omega-6)
    3. Astaxanthin
    4. Curcumin
    5. Fucoxanthin
    6. Fenugreek
    7. Taurine
    8. Statins
  19. Safety and Toxicology
    1. Mercury in Fish and Fish-based Supplements


Edit1. Sources and Active Molecules

1.1. Fish oil contents and sources

Fish oil is a term used to refer to a certain solution of fatty acids (a component of dietary fat) called eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); they are referred to as oils from 'fish' (despite a small presence in poultry and presence in neural tissue of all species) as serum EPA and DHA concentrations tend to scale with fish intake, with Americans[2] usally having lower serum levels of these two fatty acids than Japanese[3] and Inuit (Greenland)[4] persons. Fish oil is the bioactive of Cod Liver Oil (alongside Vitamin A and Vitamin D) and Krill Oil (in the form of phospholipids rather than triglycerides).

Any fish oil product may contain more omega-3 fatty acids that are neither EPA nor DHA (for example, the intermediate called DPA[5]) and may contain fatty acids that do not belong to the omega-3 class; exact levels of fatty acids and omega-3 fatty acids depend on the source of fatty acids and processing, and tend to be stated on the label.

Fish oil refers to two fatty acids, called eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These are both omega-3 fatty acids. They are found in very high levels in fish, as compared to terrestrial animals.

With other additives that may or may not be included, depening on processing:

  • Methylmercury contamination[6][7][8] although this is dependent on initial source of the oil (fish) and company dependent processing. More info in the safety and toxicology section on this topic
  • PCB/dioxin contamination[9][10]
  • Organochlorine contamination[6][11].

Generally any toxin that is released into the water and is fat-soluble in nature (and thus can be stored in the tissues of fish) has potential to be found in fish oil supplementation. If possible, fish oil supplements from non-predatory and non-bottom feeding fish (such as sardines, herring, or mackeral) should be used, as mercury levels (used as a standard by which to assess 'contaminants' in general) typically are elevated in fish that consume other fish and build up stores of mercury and PCBs[12][13], and bottom-feeders that feed on carcasses of fish and accumulate toxins and minerals.[14] Depth of forage may also be correlated with mercury levels, making surface fish safer.[15]

Fish oil can have the same contaminants as fish, but this is dependent on the quality of the processing and the source of oil. Low predatory fish like sardine, cod and prawn (Krill Oil) are safer and should be used, if the higher cost of oil is not a concern.

1.2. Structures and Properties

The active components of fish oil are generally considered to be the two omega-3 (also written as n3 or ω3) fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Both fatty acids are similar in structure, although DHA a tad longer (eico- refers to a fatty acid with 20 carbons in its chain, while docosa- refers to a carbon chain 22 in length). The term Omega (ω) is used to refer to the 'end' of the fatty acid, and the omega designation of any fatty acid is the distance from the end of the chain where the first double bond occurs.

Any fatty acid that has a double bond is unsaturated (if only once, monounsaturated; if many times like both fish oils, polyunsaturated or PUFA) and thus has an omega designation; saturated fatty acids lack double bonds and thus have no omega designation. The diagram below indicates double bonds via parallel lines

The shortened nomenclature for EPA is 20:5n3 while 22:6n3 is for DHA; the first number refers to the carbons in the sidechain, while the second refers to the overall count of double bonds (and the final number referring to the omega designation).

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are omega-3 polyunsaturated fatty acids, that are 20 and 22 carbons in length, respectively.

1.3. Supplemental sources of Omega-3 fatty acids

For dietary ingestion of EPA and DHA from fish products, there are a few choices; triglycerides, reesterified triglycerides, ethyl ester (the pharmaceutical Lovaza), and phospholipid (crustacean sources such as Krill Oil). These four all confer dietary EPA and DHA, but krill oil is approximately a third better absorbed than triglyceride form[16][17] and ethyl ester the reverse (if fish oil triglycerides are standardized to 100% absorption, ethyl esters reach 73%[18]), which seem to confer less benefits relative to triglycerides on a gram per gram basis.[19][20] Re-esterification of triglycerides appears to enhance their absorption (124% of triglycerides[18]), but although this is somewhat comparable to phospholipid formation, the two have not been directly compared.

Due to fish oil supplements being derived from fish, they are classified as vegetarian but not vegan. Currently, the only significant vegan source of DHA is microalgae (phytoplankton)[21] and its supplement referred to as 'algae oil'.[22][23] The DHA component is equivalent to fish sourced DHA in cardiovacular health[24][25] and seems to have comparable safety[26] suggesting that they are interchangeable.

Other vegetarian sources of omega-3 fatty acids tend to have the parent structure of alpha-linolenic acid (ALA; not to be confused with Alpha-Lipoic Acid which shares the acronym) and significant plant sources of ALA include Hemp Protein and flaxseed, while supplements with a smaller ALA quantity include Spirulina and Chlorella.

Vegan sources of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are limited to supplements derived from phytoplankton.

1.4. DHA deficiency and Regulation of DHA

As all fish oil supplementation is derived from fish, these products are animal byproducts. Their usage would thus not be vegan. It should be noted that absolute depletion of EPA and DHA in the blood of vegans does not occur,[27] which is thought to be due to adaptation mechanisms[28] such as increased hepatic production of DHA from the omega-3 precursor ALA[29] [30][31] with no influence on cerebral synthesis[32] and downregulation of enzymes that consume DHA including cyclooxygenase-1 (COX1)[33] and phospholipase A2[34], which prolongs the half-life of DHA.[35] It should be noted that DHA synthesis is decreased with dietary DHA surplus[36] and this adaptive effect is thought to be the reason why there is little to no clinically relevant omega-3 deficiencies in society.[37][38]

Although vegans and vegetarians tend to have reduced circulating EPA and DHA concentrations, they also possess adaptive mechanisms to attenuate the decline. An absolute depletion of these fatty acids is not seen in one living system. An absolute depletion requires generational deprivation.

Fatty acids (polyunsaturated) are converted from one another in the body via an enzyme class known as desaturases, and the dietary requirement for omega-3 and omega-6 (the essential fatty acids) are due to a lack of the delta (Δ) 15 and Δ12 desaturase, respectively.[39] The enzyme known as Δ6 desaturase is the rate limiting step for producing DHA in the body,[40][41] and supplementation of fish oil tends to circumvent this rate limit; alternatively, the enzyme itself can be targeted to increase DHA concentrations in the body (seen in the Fat-1 mouse line, which naturally has all the benefits of fish oil supplementation without requiring ingestion thereof[42][43][44]) and this is known to be induced by Fucoxanthin.[45][46] Without any modifications and assuming average fish intake, the rate of ALA conversion into DHA tends to be in the 2-10% range.[47][48]

After fish oil supplementation, the parent omega-3 fatty acid is converted into EPA and, via EPA, turned into DHA via a chain of enzymes, where Δ6 desaturase is the rate limiting step. This enzyme is an active regulator of bodily DHA levels. Increasing the activity of this enzyme will increase DHA stores in the body and is likely synergistic with dietary alpha-lipoic acid (ALA) intake in increasing bodily DHA stores.

In animal models (rats[49] and primates[50]) a DHA deficiency in critical tissue (retina and brain) only occurs after restricting multiple generations but does result in functional impairment of the eyes and brain.[51][52]

True omega-3 deficiencies (which are related to DHA deficiency) can only be induced through multi-generational depletion of dietary fish oils. Issues with visual processing are the most adverse of the cognitive effects that can result from this depletion.


Edit2. Eicosanoids (How Fish Oil Works)

The term 'eicosanoid' refers to any molecule derived from lipids, as long as it is over 20 carbons in length and serves as a signalling molecule. All of the following sections (resolvins, protectins, and prostaglandins) are subcategories of eicosanoids.

2.1. Bioactivation of Eicosanoids

An enzyme located on the cellular membrane called Phospholipase A2 is able to hydrolyze (free up) a fatty acid from the middle of a glycerol backbone upon activation, and due to both DHA and arachidonic acid being in the middle of a triglyceride frequently they are frequently mobilized by Phospholipase A2.

Phospholipase A2 is stimulated by seizures,[53][54] ischemia,[55] and NMDA-receptor stimulation[56] as well as various inflammatory cytokines (IL-1β,[57] TNF-α,[58] and PMA[59]) and oxidation products.[60] The molecules that stimulate phospholipase A2 tend to be associated with cellular and metabolic damage, and thus eicosanoids are thought to be hormetically induced.

The enzyme phospholipase A2 releases stored polyunsaturated fatty acids in response to stress. Eicosanoids from docosahexaenoic acid (DHA) and arachidonic acid (AA) are released after stressors influence the cell. Stressors include inflammation and oxidation.

The cellular membrane ratio of omega 3 to 6 fatty acids is important as phospholipase A2 is not discriminatory as to which polyunsaturated fatty acids it releases, and the eicosanoids that are produced when a cell is stressed correlate directly with the polyunsaturated fats that make up the membrane.

The standard western diet (mostly in reference to the US) tends to have a ratio highly favoring omega-6 fatty acids in the range of 15-20:1 approximately (varies depending on source).[61][62][63] A modern European diet (using data from the UK and Britian) is not significantly better at around 15:1[64] modern day Japan has a more desirable ratio at around 4:1.[65] Interestingly, India has a large disparity between rural areas (5-6.1:1) and urban areas (38–50:1).[66]

It has been hypothesized that paleolithic humans had an omega ratio around 0.79 (slightly more omega-3 than omega-6) due to low dietary omega-6 intake[61][67] and it has been reported that the diet of Grecians prior to 1960 was in the 1-2 range;[68] interestingly wild animals tend to also have something similar to a 1:1 ratio.[69][70] due to these low ratios and the evidence that omega-6 consumption has increased in the past 150 years due to technological development[68][61] there does appear to be a paleolithic argument for a normalized ratio.

The ratio of omega 3 to omega 6 fatty acids in the cellular membrane (either as an EPA:AA ratio, a DHA:AA ratio, or an EPA+DHA:AA ratio) is a quantifiable way of predicting which eicosanoids are produced in response to stress.

2.2. Resolvins

Resolvins (resolution-phase interaction products[71]) are potent signalling molecules involved in inflammation[72] derived from omega-3 fatty acids, and those that are derived directly from EPA (without requiring metabolism into DHA) are referred to as the E series, while those derived from DHA are called the D series.[73][74] The E series or resolvins involves one of two pathways, either the lipoxygenase pathway (favoring R isomers) or the aspirin-inducable COX2/P450 pathway (favoring S isomers); regardless of the pathway, the first intermediate after EPA is known as 15-HEPE.[73][74][75] DHA and the D series follows a similar motif (having a LOX pathway and an aspirin inducable pathway[76][77][71][78]) although its first intermediate is 15-H(p)DHA[74], which has been confirmed to increase in plasma following supplementation of fish oil.[74]

The aspirin-inducable conversion requires both the presence of aspirin and the COX2 enzyme (as aspirin modifies the actions of the enzyme in this regard[79][80]), which appears to convert resolvins to R isomers rather than S isomers.[78] COX1 is inactive in this regard,[81] acetominophen and indomethacin are unable to exert the same effects,[78] and treatment with aspirin alone does increase these two molecules due to DHA already being present in the body.[78]

Resolvins are molecules named after their ability to 'resolve' inflammation. They are produced by eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These are the molecules responsible for the synergy between fish oil and aspirin.

Resolvins of the E series include:

  • Resolvin E1 (RvE1 or 5S,12R,18Rtrihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid[71])
  • Resolvin E2 (RvE2 or 15S,18R-dihydroxyeicosapentaenoic acid[71])

Resolvins of the D series include:

  • Resolvin D1 (RvD1 or 7S,8R,17R-trihydroxy-docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid and induced by aspirin treatment)
  • Resolvin D2 (RvD2 or 7S,16R,17S-trihydroxy-docosa-4Z,8E,10Z,12E,14E,19Z-hexaenoic acid also induced by aspirin)
E series resolvins are derived from EPA, while D series resolvins are derived from DHA.

RvE1 has been identified to be a ligand of the ChemR23 GPRC receptor,[82][83][84] which is analgesic.[72] The resolvin of the D series of similar structure (RvD1) also appears to be a ligand.[72]

Resolvins of the D series have antiinflammatory properties by inhibiting TNF-α induced cytokine expression in microglia in the picomolar range (IC50 of 50pM).[78] They are deactivated by oxidation, where they are converted to oxidized resolvins (at either the 8 or 17 position).[71]

2.3. Protectins

Protectins are molecules that are produced from DHA and are structurally docosatrienes, alongside resolvins they mediate many benefits associated with fish oil ingestion.[71]

  • Neuroprotectin D1 (10,17S-docosatriene of the lipoxygenase pathway[85])
  • Marisen 1 (7,14S-dihydroxy-docosa-4Z,8,10,12,16Z,19Z-hexaenoic acid of the lipoxygenase pathway[71])
Protectins are molecules derived from docosahexaenoic acid (DHA), but they do not belong to the D series of resolvins.

Marisen 1 is named after macrophage mediators in resolving inflammation and is present in macrophages and platelets and formed via the actions of 12-lipoxygenase,[71] but beyond that is not fairly well researched.

Neuroprotectin D1 (NPD1) is more well understood. Produced by a 15-lipoxygenase like action[86] after cleavage from phospholipase A2[85] where the metabolite 17SH(p)DHA (same as the D series of resolvins) is converted into a 16(17)-epoxide and then reconfigured to NPD1.[87]

NPD1 appears to have potency antiinflammatory properties (by dysregulating IL-1β induced COX2 induction[87]) in the brain in response to stroke and ischemia[88] and anti-Alzheimer's actions by preventing the inflammatory response to the protein agggregates seen in the disease state with an IC50 of 50nM (β-amyloid,[89] may also reduce levels of the pigmentation[90]). This protection is via a PPARγ dependent mechanism[89] and as DHA has been noted to reduce amyloid buildup in animals and in vitro[91][92][93] it is thought that NPD1 mediates these effects.

The first metabolite of DHA can be converted into either D series resolvins or protectins. Neuroprotectin D1 (NPD1) is a notable protectin with potent anti-Alzheimer's actions and neuroprotective properties.

2.4. Prostaglandins

While both resolvins and protectins are fatty acid chains derived from EPA or DHA, prostaglandins are characterized by having a pentacyclic ring in their structure (ie. a pentagon in the fatty acid sidechain similar to furan fatty acids).

Prostaglandins include:

  • Prostaglandin J2 (15-deoxy-Δ12,14 prostaglandin J2)[94][95]
Prostaglandins are eicosanoid metabolites with a pentacyclic structure (pentagon) in their side-chain. They are also bioactive metabolites of polyunsaturated fatty acids.

15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2 or just Prostaglandin J2) is a derivative of that can activate PPARγ with an EC50 of around 20μM[96][94][95] and inhibit platelet aggregation with an IC50 in the 5-10nM range.[97][98]

Prostaglandin J2 is related to PPARγ activation and platelet aggregation inhibition.

Prostaglandin F2α has been confirmed to be increased in young men following supplementation of fish oil, and has been noted to increase concentrations of Thromboxane B2 (inactive metabolite of the omega-6 eicosanoid thromboxane A2).[99]


Edit3. Molecular Targets

3.1. PPAR Receptors

Fish oil fatty acids interact with the peroxisome proliferator-activated receptor (PPAR) system, which are a class of receptors (PPARα, PPARβ/δ, and PPARγ) that seem to respond to dietary lipids and similarly structured molecules. They are highly involved in the treatment of diabetes and metabolic syndrome (via the drug classes of fibrates and thiazolidinediones), with varying effects on fat mass (PPARα increases beta-oxidation of fatty acids,[100] while PPARγ promotes fat storage but improves insulin tolerance;[101] PPARδ appears to be similar to PPARα in this regard[102]).

PPARs are fairly general receptors, as their binding site is 3-4 times larger than other receptors[103], which means they have a very general binding capacity.

The PPAR system is a receptor class activated by dietary fatty acids and pharmaceuticals highly involved in lipid and glucose metabolism. It is a druggable target for diabetes and obesity (via PPARγ and PPARα/δ respectively).

15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2) is an endogenously produced highly effective PPARγ ligand with an EC50 of 20μM[96][94][95] and its induction (Fuligocandin B from Fuligo candida[104]) carries the benefits of targeting PPARγ.

18(S)HETE from aradchidonic acid metabolism activates PPARβ and γ with moderate affinity (20μM and greater than 50μM)[105] and cellular incubation with parent arachidonic acid (without controlling for metabolites) appears to have an EC50 of 1.6μM.[106]

Both the omega-3 and omega-6 metabolisms have PPARγ activators.

Although a few eicosanoids of both omega-3 and omega-6 origin appear to activate PPARα[105][107] it appears that Leukotriene B4 (from arachidonic acid metabolism) is the most biologically potent and relevant with an EC50 of around 100nM.[108] The arachidonic acid (AA) metabolite 18(S)HETE also appears to be 10-fold weaker (1μM; R isomer much weaker[105]) but is better able to recruit the coactivator of SRC-1 (30% the concentration required for 18(S)HETE relative to LKB4[96]). Parent AA is a weak activator per se (50μM or more[96]) but past studies that did not control for metabolites noted more efficacy due to its metabolites (1.2μM[106]).

PPARα is activated by metabolites of the arachidonic acid (omega-6) pathway. Although the significance of this information is unknown, normalizing a ratio of omega 3:6 may reduce overall PPARα stimulation.

3.2. AMPK

Adenosine monophosphate kinase (AMPK) is a nutrient signalling molecule that is antagonistic of mTOR and activated in periods of nutrient deprivation; it is also the molecular target of various supplements like Berberine or the pharamceutical Metformin. The activation of AMPK (seen with both EPA[109] and DHA[110]) is partly downstream of PPARγ (noted in general[111] and with EPA[112]) and likely mediated by the eicosanoids mentioned in the PPARγ section.

EPA has been found to activate AMPK in adipocytes via insulin-indepedent means (not requiring activation of PI3K)[109] and fish oil in macrophages.[110] The α1 subset of AMPK appears to be mostly affected[110] and both Thr172 phosphorylation (on AMPK) and Ser431 (on LKB1) noted,[112][113] and DHA has also shown efficacy in isolation in promoting AMPK activity.[110][114][115]

Fish oil activates AMP-activated protein kinase (AMPK). This is partly due to the eicosanoids activating PPRγ, which increases the activity of AMPK.

Via AMPKα1 activation, DHA may increase SIRT1 expression[110] and suppress inflammation by hindering (via deacetylation[116]) NF-kB signalling;[117] this is also a plausible antiinflammatory pathway of fish oil. EPA has been noted to dysregulate inflammatory signalling in adipocytes (usually by suppressing the actions of TNF-α),[118][119]

Activation of AMPK by EPA may underlie release of adipokines,[120][109] some inflammation (macrophages can hinder AMPK activation via SIRT1[117] and EPA preserves this[110]), improved endothelial function,[112] hepatoprotection,[113] insulin sensitivity (related to the liver),[121] and autophagy (seen with DHA[114] but a normal consequence of AMPK activation as seen via p53, which induces AMPK[122][123]).

AMPK activation has been confirmed in mice given 500mg/kg EPA (no reference drug, but just over a doubling in vasculature[112]) and other studies using fish oil at 1mL/kg[113] or 15% of the diet.[121]

AMPK activation has been noted to occur in rodents following oral ingestion of EPA. Since knockout mice (those without AMPK) have failed to show benefits from omega-3 supplementation, it appears that this pathway is very relevant to the benefits of omega-3 fatty acids.

3.3. FFA receptors

The free fatty acid receptor (FFA), also known as GRP120, is a G-protein coupled receptor (rhodopsin-like[124]) with a short (361 amino acids; 97.5% homologous between rodents and primates[125]) and long (377 amino acids; possibly only in humans[125]) variation expressed mostly in enteroendocrine L cells.[126] This receptor is named the free fatty acid receptor as it responds to a variety of fatty acids[127] and some omega-3 fatty acids (ALA and DHA) have been confirmed to be agonists with DHA stimulating activity to 276+/-25% (short variant) and 177+/-13% (long) at a concentration of 100μM.[128] Elsewhere, mixtures of omega-3 fatty acids have been able to signal via the receptor.[126]

Activation of this receptor by omega-3 fatty acids is known to secrete some gut hormones (Glucagon-like peptide 1[129][130] and cholecystokinin[131]) and is involved in insulin sensitization secondary to antiinflammatory effects[126] and possible anti-obese effects (as loss of GRP120 is a risk factor for obesity and GRP120 knockout mice are obese[132]).

It has not yet been confirmed whether DHA and EPA are direct agonists of the receptor or whether they work via eicosanoids, although the ability of alpha-linolenic acid to activate the GRP120 suggests the former.

Activation of GRP120 (free fatty acid receptor) through fish oil supplementation and/or derivative eicosanoids has been confirmed in animals. This may underlie some of the biooactivity of fish oil supplementation.

Other fatty acid receptors exist (all with a GPR designation) including FFAR1 (GPR40), FFAR2 (GPR43), FFAR3 (GPR41), and GPR84.[133] FFAR1 responds mostly to medium chain fatty acids (palmitic acid and linoleic acid[134][135]) and both FFAR2 and FFAR3 respond to shorter chain fatty acids (acetate and butyrate[136]) with GPR84 being the sensor for medium chain fatty acids (lauric acid[137]). Although these are free fatty acid receptors, they are not seen as molecular targets of EPA nor DHA due to the long length of fish oil fatty acids.

Other free fatty acid receptors are not likely molecular targets of fish oil supplementation, as they respond to shorter chain fatty acids.


Edit4. Pharmacology

4.1. Absorption

EPA and DHA tend to be digested and taken up as normal dietary fats, by getting packaged into micelles in the intestines and being subsequently dropped off at fat cells and muscle cells by chylomicrons (a transport molecule) before the chylomicron remnant goes to the liver.

If the fish oils are microencapsulated (which occurs in some functional foods to avoid a fishy taste) they tend to be absorbed in the upper small intestines[138] although a large bit is incorporated into the intestinal wall as well.[139]

4.2. Bodily stores

Bodily loading of fish oil seems to be maximal after approximately 3 weeks of supplementation with no significant difference between doses tested (210-630mg EPA and 150-450mg DHA).[140]


Edit5. Neurology

5.1. DHA concentrations

It has been hypothesized that dietary DHA is required for optimal neural functioning due to some evidence suggesting a diet low in DHA reduces brain phospholipid content by 32% (high dietary ALA) or 53% (low ALA), relative to a diet high in DHA,[28] although losses of DHA from the brain are somewhat difficult over the short term in non-neonates and seem to be regulated[141][142] and neonates seem more sensitive, with DHA deprivation from young mice resulting in DHA losses in the brain within 2 weeks.[143] Losses have been reported in adult primates on dietary restriction of DHA (and are likely to apply to huamns), but this requires a time period of 18 months[144] or 5 years (70% reduction)[145] with the inclusion of Alcohol to deplete DHA stores.[144][145]

Short term dietary restrictions, in adults, are unlikely to modify cerebral concentrations of docosahexaenoic acid (DHA). However, prolonged absence of DHA in the diet seems to be able to progressively reduce DHA concentrations in the brain.

5.2. Aggression

It has been hypothesized that aggression is a symptom of DHA deficiency,[146] in which case supplemental DHA would alleviate this deficiency.

In otherwise healthy persons, DHA appears to prevent excessive aggression in times of stress[147][148] and has been found to prevent a decline in aggression during destressing follow-up periods.[149] These effects are seen (like depression and stress) in the range of 1.5g daily, and don't appear to occur at 150mg DHA daily.[148] A reduction in aggression was also seen in a group of young men without a previous history of agression at a dose of 672mg/day DHA for 3 months.[150]

An exception may be schoolchildren, who showed benefit at 3.6g per week in one study.[151] Another study in children aged 8-16 years old given a drink containing 1g of omega-3 fatty acids a day (consisting of 300 mg of DHA, 200 mg of EPA, 400 mg of alpha-linolenic acid, and 100 mg of DPA) for 6 months also showed a reduction in several measures of aggression compared to a placebo drink of similar flavor and consistency.[152]

DHA seems to reduce aggression when deficient (as aggression may be a side-effect of deficiency) and has an effect on normalizing aggression levels, which can be good in the face of stress, but it has been noted to prevent a decline in stress. These results may be confounded with influences on noradrenaline. See the 'Stress' section for more information.

5.3. Memory and Learning

DHA is investigated for its role in memory formation as higher serum DHA concentrations are correlated with greater verbal fluency skills in older humans[153] and a deficiency of DHA is known to damage rat memory processing.

For animal models, administration of DHA (300mg/kg is the standard dose) appears to promote cognition with improvements noted in reference memory (without affecting working memory) in otherwise healthy rats.[154]

There is animal evidence to support docosahexaenoic acid (DHA) improving memory in otherwise healthy rats.

One study conducted in otherwise healthy young (18-25) persons noted that, after 6 months of supplementation with 2g Lovaza (750mg DHA; 930mg EPA) that working memory was enhanced as assessed by a verbal n-back test (with improvements in 3-back but not 1 or 2-back); this was deemed to be independent of dopamine metabolism but instead correlated with the EPA and DHA content or Red Blood Cells (RBCs; up 75% from 2.9+/-1.0% for DHA, and up 350% from 0.4+/-0.1 for EPA) when looking at the RBCs of persons low in DHA.[155] Elsewhere, youth who have low dietary intake of fish have experienced improved memory retention and reaction time with supplemental DHA at 1,160mg over 6 months.[156] Some isolated studies not reporting dietary intake of fish oil also report benefits to memory formation (as well as attention and reaction time).[157] Interventions in older adults tend to note benefit in persons with[158] and without[159] apparent cognitive decline.

Some studies fail to find a significant benefit of fish oil supplementation on cognition in healthy adults (400-1,800mg EPA+DHA,[160] 1,400mg EPA and 800mg DHA,[161] or 1g EPA+DHA over 12 weeks[162]) with one of these studies[161] having an exclusion criteria of 'no more than once weekly' for fish intake but otherwise diet was not reported.

There is human evidence to support an increase in memory (working and episodic) associated with DHA supplementation. Although it cannot be ruled out, it is plausible that this will only occur in people with low dietary DHA intake.

5.4. Depression

A meta-analysis on fish oil supplementation and depression (inclusive of disease states such as schizophrenia or bipolar disorder)[163] able to assess 28 studies with a dosage range of 136-6,200mg EPA and 88-3,400mg DHA (Postpartum or perinatal depression,[164][165][166][167][168] major depression disorder or depression without other cognitive diseases,[169][170][171][172][173][174] depression associated with fatigue,[175][1] bipolar disorder,[176][177][178][179] schizophrenia,[180] Parkinson's disease,[181] self-harm,[182] personality disorders,[183] or no significant disease state or just mild depression[184][185][186][187]) noted that a higher EPA:DHA ratio was predictive of anti-depressive effects and that the three studies using pure DHA[166][170][167] outright failed to exert antidepressive effects. Oddly, 1g of EPA supplementation (as ethyl ester) appears to be more effective than 2-4g in one trial[171] or at least 2g fails to outperform 1g[178] and the meta-analysis came to the same conclusion where supplemental EPA dose was inversely related to efficacy (with higher doses being less effective).[163]

Beyond identifying the efficacy of lower doses, this meta-analysis found evidence for publicity bias (was unsure if this was due to hetereogeneity in the studies assessed as it was very inclusive or other influences) and suggested that persons with higher baseline depression experienced more benefit, with the group with low depressive symptoms having a reduction of −0.074pts on mean depression (95% CI of −0.317 to 0.169) that was not statistically significance but the higher depressive group having a reduction of −0.605 (95% CI −0.871 to −0.339).[163] The robustness of the studies (assessed by Jadad) was similarly hetereogeneous with some poor quality studies included.[163]

Supplementation of 1g eicosapentaenoic acid (EPA) appears to benefit depression most. Docosahexaenoic acid (DHA) is not associated with any significant antidepressive effects. The antidepressant effects of EPA are only significant in severely depressed people.

It is plausible that fish oil is an augmentor of antidepressants, as the above meta-analysis did note that most trials conducted in major depression or disease states were also mediated with standard antidepressant drugs (such as lithium).[163] At least one study has noted that fish oil (in isolation at 1,000mg ethyl-EPA) is comparable to the SSRI drug fluoxetine (20mg) but also supports the idea that combination therapy is best, as response rates were in the range of 50-56% (monotherpaties) and rose to 81% with both.[188] This synergism has been noted in animal studies with traditional anti-depressants (fluoxetine and mirtazapine)[189] and with nutraceutical anti-depressants such as Uridine.[190]

There is evidence to support fish oil acting as an antidepressant by itself, but there is also evidence to support significant effects to come from combination therapy. Combination therapy means taking fish oil alongside a proven antidepressant.

In otherwise healthy elderly adults with minor depressive symptoms, fish oil supplementation does not appear to further increase well-being and reduce depression at 1800mg EPA+DHA,[184] and has failed to reduce depressive symptoms (or increase well being) in adults who do not report depression.[191][192]

There is insufficient evidence to support a mild antidepressive effect in people who report mild but not debilitating depression. Fish oil supplementation appears to be ineffective for mild depression in the studies that investigate it.

5.5. Bipolar Disorder

Fish oil supplementation is hypothesized to aid bipolar symptoms as reference drugs (lithium carbonate and valproate) reduce neuronal signal transductance systems[193][194] which appears to have been noted with omega-3 fatty acids in regards to arachidonic and phospholipid signalling.[179] Bipolar disorder does appear to also be associated with alterations in membrane lipids, but this is more related to GLA and the omega-6 fatty acids than it is to fish oil.[195]

However, despite a preliminary study noting that fish oil supplementation may aid symptoms of bipolar disorder at 9.6g daily (6,200mg EPA and 3,400mg DHA)[179] and (albeit cautious) promise for depressive symptoms mentioned by one meta-analysis on the topic,[196] a followup study using smaller doses (2g twice a day, totalling 1,680mg EPA and 1,120mg DHA) with or without 1g cytidine delivered via CDP-choline (twice daily; forms Uridine in the body[197]) failed to replicate the results over a similar time period of 16 weeks, and actually reported a nonsignificant trend to worsen symptoms.[198]

There is mixed evidence regarding fish oil supplementation and bipolar disorder. The limited studies on the topic are too different to compare, as they use very different dosages. Although a beneficial effect cannot be ruled out, a worsening effect is also possible.

5.6. Stress

Fish oil supplementation in rats (at 5% food intake) was found to normalize the stress response after being subject to footshock, a research test used to mimic long-term environmental stress.[199] This has been replicated in other models on animals and in humans with DHA supplementation at high doses (1.5-1.8g DHA) daily in which adrenaline response to stress is attenuated.[146][200] In longer term models to assess cortisol (long term stress hormone), students taking 20 exams had a similar decrease in noradrenaline (-31%) at 1.5g DHA daily, although no changes in cortisol were noted.[201]

In regards to stress, both EPA and DHA seem to have implications. EPA from modulating some immune functions associated with stress[202] and DHA is tied in with aggressive increases during stressful times.[203]

Interestingly, a low dose of 762mg EPA+DHA daily can reduce noradrenaline levels even in healthy non-stressed persons.[204]

5.7. Glucose Metabolism

A deficiency of omega-3 fatty acids has been noted to reduce glucose metabolism in the brain in rats[205] thought to be related to reduced GLUT1 transporters[206] which is amendable with supplemental omega-3 fatty acids (in vitro).[207][208]

In primates, DHA supplementation (150mg/kg) has been noted to improve neuronal glucose uptake[209] although this does not appear to occur in humans per se (independent of age);[210] there does appear to be an inverse correlation between cerebral glucose utilization and serum triglycerides[210] suggesting that treatment of dyslipidemia may be beneficial.

It is unlikely that fish oil supplementation increases cerebral glucose metabolism in healthy individuals. People with metabolic syndrome or high triglyceride levels might experience a benefit secondary to reducing triglycerides, but further study is needed to confirm this effect.

5.8. Blood Flow and Oxygenation

Isolated EPA has been noted to modulate cerebral blood flow in spontaneously hypertensive rats at 100mg/kg for 8 weeks.[211]

As assessed by haemodynamics in functional near IR spectroscopy (NIRS) where total blood hemoglobin is closely correlated to blood volume and oxygenation rates can be measured[212] it has been noted that in otherwise healthy young adults not consuming more than one fatty fish product per week who then recieved 450mg DHA and 90mg EPA for 12 weeks was able to increase cerebral oxygenation during cognitive testing (without affecting deoxygenated hemoglobin as total hemoglobin increased);[213] this study is duplicated in Medline.[214]

Fish oil appears to promote blood flow to the brain in otherwise healthy adults, who have low dietary fish intake.

5.9. Stroke

Most epidemiological evidence,[215][216][217][218] but not all,[219] suggest a reduced risk of stroke associated with high dietary fish consumption particularly in elderly persons[218] and following standard dose-response;[215] this is thought to be related to the omega-3 fatty acids[220] and particularly DHA.[221][28]

Intravenous administration of fish oil triglycerides to mice given a stroke (hypoxia/reperfusion; 100-375mg/kg fish oil) noted that a 43-47% reduced infarct size resulted with both pre-treatment and up to 2 hours post-stroke,[222] and 100mg/kg of EPA (as ethyl ester) for 8 weeks in spontaneously hypertensive stroke-prone rats has noted a modulation of cerebral blood flow.[211]

It is possible that fish oil supplementation has both a therapeutic and preventative role for stroke victims.

5.10. Dementia and Alzheimer's

The amount of DHA complexed with Phosphatidylcholine in plasma appears to be negatively correlated with the risk of dementia in humans[223] and high dietary intakes of fish have been noted to be protective against the rate of developing dementia and related cognitive decline disease states in older and middle aged persons.[224][225][226]

When assessing older adults, higher cerebral levels of EPA (surprisingly, not DHA) are related to less atrophy of select brain regions (hippocampus, right amygdala) when followed over 4 years[227] and lower erythrocytic EPA and DHA are associated with reduced brain mass in older adults in cohort studies.[228] These results suggest a protective role of EPA, and 2,000mg of supplemental DHA for 18 months in older adults has failed to reduce the rate of atrophy.[229]

Higher fish intake is associated with a lower risk of developing dementia, and reduced docosahexaenoic acid (DHA) levels in serum are associated with a higher risk of dementia. Eicosapentaenoic acid (EPA) appears to be associated with preserving brain mass over time.

A higher intake of omega-6 relative to omega-3 can be associated with increased activity of COX enzymes as they are competing substrates[230] although the subsequent production of PGE(2) (known to increase amyloid secretion[231] via inducing γ-seceratase[232]) which is known to be reduced with fish oil[233] appears unrelated to DHA-induced suppression of amyloid secretion.[234]

As mentioned in the protectin section, it is plausible that the mechanism of protection against amyloid buildup is mediated via Neuroprotectin D1 as it potently (EC50 of 50nM) suppresses amyloid formation[89] and promotes its removal[90] via PPARγ-dependent mechanisms.[89]

Prostaglandin E2 (PGE2) induced amyloid buildup does not appear to be related to neuroprotection, in regard to Alzheimer's, but it is likely related to neuroprotectin D1.

In animals, provision of DHA at 300mg/kg (rat dose) for 12 weeks appears to promote cognition, memory, and reduce the rate of cognitive decline in a model of Alzheimer's disease characterized by β-amyloid pigmentation.[235][236][237] Furthermore, the dendritic/synaptic decay seen in Alzheimer's disease[238][239] appears to be reduced with provision of DHA[240] which is thought to be the mechanisms of neuroprotection and further thought to be synergistic with Uridine supplementation.[241][242]

Animal evidence appears to support the role of DHA in high doses (300mg/kg in rats, which is an estimated human dose of 48mg/kg or 3.2g DHA for a 150lb person).

In people with Alzheimer's, 2,000mg DHA (no EPA supplementation) from algae over 18 months has failed to benefit cognitive decline[229] and another study using 1,700mg DHA and 800mg EPA in persons with Alzheimer's for 6 months has failed to significantly attenuate the rate of cognitive decline as assessed by MMSE[243] and failed to alter neuropsychiatric symptoms (both citations are the same trial).[244]

In human studies on age-related cognitive decline that are not Alzheimer's patients, it appears 900mg DHA may reduce the rate of cognitive decline[245] but 500mg DHA and 200mg EPA over 24 months has failed to do so.[246] The latter study, however, failed to find any rate of cognitive decline in either group and may not accurately represent fish oil.

Studies using practical and high levels of fish oil supplementation in people with Alzheimer's disease have failed to find practical benefits, but studies in older adults without AD have suggested that DHA may be able to attenuate the rate of cognitive decline. The reason for this disparity, if it exists, is not known at this time.

5.11. Pain

Resolvin E1 (RvE1) signals for analgesia via the Chem23 receptor, and is active independent of fish oil supplementation (injections of 0.3-20ng RvE1; more potent than 10mcg of the COX2 inhibitor NS-398);[72] its metabolic inactivation by oxidation (oxo-RvE1[247]) is metabolically inactive.[72] It appears that activation of the Chem23 receptor via RvE1 inhibits ERK[248] and more specifically TNF-α induced activation of ERK[72] which would signal to TRPV1[249] to mediate the perception of pain. Overall, it is hypotheiszed that RvE1 siganllings for pain releif primarily by dysregulating TNF-α and its normal induction of glutamate release form neurons, which activates ERK to induce pain via TRPV1.[72]

Although RvE1 was researched above, RvD1 (from DHA) appears to also activate the Chem23 receptor[72] and the parent fatty acids of EPA and DHA were also tested but were approximately 10,000-fold weaker.[72]

Resolvin E1 (from EPA supplementation) and Resolvin D2 (from DHA) appear to act via a novel receptor to prevent the pro-inflammatory cytokine known as TNF-α from inducing pain. On a molecular level (how much of a molecule is required to induce effects), RvE1 and RvE2 are remarkably potent.

For human studies, supplemental fish oil has been found to reduce pain in persons with inflammatory joint pain as assessed by patient reports and NSAID consumption (rescue medication, which was reduced) but not by physician reports.[250]


Edit6. Cardiovascular Health

6.1. Mechanisms

CETP is a transport protein that transports cholesterol from HDL to either vLDL or LDL (apolipoprotein B containing lipoproteins[251]) in exchange for triglycerides,[251][252] and reducing the activity of CETP increases HDL-C[251] possibly in hyperlipidemics only[253] while CETP activity itself is positively correlated with LDL-C.[252][254] Due to this and associations between CETP and high cholesterol[255][256] increasing the activity of CETP is seen as pro-artherogenic (increasing LDL-C while reducing HDL-C, opposite of the desired therapeutic intervention) and its inhibition seen as desirable.

The inhibition of CETP is further desired as a triglyceride reducing treatment[257] as the exchange for cholesterol from vLDL/LDL towards HDL-C is a 1:1 exchange with triglycerides;[258][251] a depletion of triglycerides from LDL and vLDL cholesterol (rather than placebo per se) has been confirmed in humans following supplementation of fish oil.[259][260][261]

Fish oil has been noted to increase CETP activity in animals[262] due to DHA and not EPA,[263] which is thought to underlie the selective induction of LDL-C seen with DHA and not EPA although it does not explain the increase in HDL-C seen with DHA.[264]

It is plausible that one of the mechanisms underlying the benefits of fish oil is cholesteryl ester transfer protein (CETP) inhibition, which is able to reduce triglycerides and increase high-density lipoprotein (HDL-C). This pathway alone, however, does not explain the effects on low-density lipoprotein (LDL-C).

6.2. Triglycerides

In regards to fasting triglycerides (TGs; risk factor for cardiovascular disease when elevated), fish oil appears to be both a potent and reliable triglyceride reducing agent for persons with hyperlipidemic (high blood TGs).

The meta-analyses that have been published indicate that fish oil is effective for general dyslipidemia (0.34mmol/L reduction[265]) HIV related dyslipidemia (7 trials of 372 persons reducing TGs 1.12 mmol/L[266]), dyslipidemia associated with renal failure (10 trials of 337 persons reducing TGs by 0.78mmol/L[267]), and diabetic dyslipidemia (24 trials of 1530 persons reducing TGs by 0.17mmol/L or 7%[268]). The range of reduction has been cited to be as high as 25-30% with 4g of EPA ethyl ester daily,[269] but more recent evidence suggests that the reduction is a tad more modest (estimated 15-20% reduction, as the magnitude does depend on baseline triglycerides).

Both EPA and DHA are able to reduce triglycerides[264] and these benefits extend to other sources of DHA including algae oil (meta-analysis[24]) and Krill Oil with comparable potency. When comparing the effects of EPA against DHA when they are used in isolation (separate trials), EPA appears to be a tad more effective (meta-analysis[264] concluding a 25.1mg/dL reduction with DHA in isolation[270][271][272][273][25][274][275][276][277] as average but a 45.8mg/dL reduction with EPA in isolation[278][279][280][281] are similar doses and baseline TGs). However, studies that assess direct comparisons between DHA and EPA[282][283][284][285][286] note superiority with isolated DHA (when doses are similar in weight; ie. 4g versus 4g[264]). It is plausible that this difference is due to EPA traditionally being dosed at a higher quantity than DHA, with fish oils typically following dose-dependence.[265]

Fish oil reliably and potently reduces triglyceride levels after several weeks of supplementation. The reduction in triglycerides is based on dosage, and it is more significant in people with high baseline triglycerides, quantified in the 15-30% range. This is pharmaceutical grade potency, which is why fish oil was patented as Lovaza (ethyl ester).

Supplemental fish oil does not appear to influence postprandial triglycerides when acutely supplemented (one dose at mealtime)[287] but has been noted to reduce postprandial triglycerides in hyperlipidemics following prolonged supplementation (27% with 4g ethyl EPA[288] or 19% with 4g fish oil[289]).

The reduction in postprandial triglycerides occurs after repeated supplementation and may be more reflective of the triglyceride reducing effect per se. Single dosages of fish oil fail to benefit postprandial triglycerides.

6.3. Lipoproteins

It is thought that DHA mediates the cholesterol increasing effects of fish oil supplementation[264] as supplementation with DHA increases HDL-C by 4.49mg/dL (95% CI of 3.50-5.48mg/dL) and LDL-C by 7.23mg/dL (95% CI of 3.98-10.5) whereas EPA nonsignificantly increases HDL-C by 0.20 mg/dL (95% CI of -0.82 to 0.41) and insignificantly influences LDL-C by 1.85mg/dL (95% CI of −3.01 to 6.71) with the sporadic instances of EPA increasing HDL-C and LDL-C[290][278][282][286][284][285] possibly being explained by conversion of EPA into DHA in the body.[264]

Fish oil supplementation, secondary to the DHA component, can increase both HDL-C and LDL-C lipoproteins in the body. It appears to increase LDL-C a bit more than it does HDL-C, and thus large doses of fish oil may not be advisable for people with high LDL-C cholesterol, unless the reduction in triglycerides is seen ias more important, or if a statin drug or similar cholesterol reducing agent like Berberine is taken alongside the fish oil.

It is possible for fish oil to reduce LDL cholesterol, but infrequent; it requires the user to not have disturbances in LDL cholesterol in the first place (normocholesterolemic)[291][292] or otherwise augments the LDL-C reducing effects of statin drugs (Nutrient-Nutrient Interactions section).

There are possible LDL-C reducing effects when fish oil is combined with statin drugs, where fish oil and statins appear synergistic in reducing LDL-C, which appears to negate the adverse LDL increase of fish oil that is possible in hyperlipidemics.

6.4. Cardiovascular Disease Risk

In secondary prevention of cardiovascular disease, a membrane ratio of 4:1 omega6:3 (average with a standard western diet is 15-16.7:1[61]) or lower is associated with a 70% decrease in total mortality[61] as assessed by a single blind prospective study.[293]

Normalizing the omega 3:6 ratio appears to be associated with cardioprotection.

6.5. Endothelial Interactions

The mechanistic basis for the improved endothelium-triggered relaxation with n - 3 PUFAs may include the suppression of thromboxane A2 or cyclic endoperoxides, a reduced production of cytokines, the augmented endothelial synthesis of nitric oxide, an improvement of vascular smooth muscle cell sensitivity to nitric oxide, and a reduced expression of endothelial adhesion molecules[294].


Edit7. Interactions with Glucose Metabolism

Note: For a complete overview on how fish oil supplementation interacts with glucose metabolism, see the pancreas and liver sections under "Interactions with Organ Systems."

Diabetic nephropathy and retinopathy analysis can be found in the organ systems section as well, although diabetic neuropathy is under Neurology.

7.1. Blood Sugar and Glycemic Control

Fish oil supplementation (following studies using ethyl ester EPA) note that fish oil consumption can somewhat reliably increase fasting glucose in the range of 2–6mg/dL, this applying to both diabetics and nondiabetics and conclusions being drawn from multiple meta-analyses(most positive[295][296][297] and some counter evidence[298]) and a trend to increase glucose is still seen in hyperlipidemic patients.[288] This increased glucose concentration is not usually met with increases in biomarkers of diabetes seen as adverse (HbA1c[296][285][297] and fructosamine[271][299]) suggesting that it may not further pathology of diabetes.

It should be noted that the increases in glucose are not observed at low doses of fish oil supplementation (6g of fish oil conferring 1,080mg EPA and 720mg DHA[300]) and appear to follow dose-dependence, with one study failing to find an influence of 4g fish oil finding an adverse increase with 7.5g (2,600mg EPA and 1.4mg DHA).[301]

There appears to be a small increase in fasting blood glucose seen with fish oil supplementation that is independent of disease state (affects diabetics, hyperlipidemics, and healthy controls), but is small (2-6mg/dL) and not associated with an increase in diabetic parameters HbA1c and fructosamine. The increase in glucose appears to occur at higher fish oil doses. Diabetics wanting to use fish oil should begin by using the lowest effective dose.
.

7.2. Insulin Sensitivity

In healthy persons, fish oil may not increase insulin sensitivity with a high fat (37%) diet when weight loss or gain prevented, at a dose of 3.6 EPA+DHA daily.[302] This study did note nonsignificant trends of improved sensitivity in individuals who had higher 6:3 ratios at baseline. Other studies note similar results in healthy persons[303] but did not record phospholipid ratios.

In otherwise healthy males, even pairing exercise with fish oil did not yeild any changes to insulin sensitivity that were attributable to the fish oil.[304] Fish oil seems to be additive to but not synergistic with exercise.

Other studies suggest improvement in insulin sensitivity in populations who typically have worse 3:6 ratios, such as the elderly[305] the metabolically unhealthy,[288][306] and the obese.[307] It should be noted that this body of evidence is not bullet-proof, and notable studies do detect no changes in insulin sensitivity even in the above populations.[308][309][310][311] Furthermore, information from our rubric show that a large amount of systematic meta-analysis' show no significant ability for fish oil to change fasting glucose or fasting insulin in type II diabetics.[312][298][295][296]

The above mechanism of increasing insulin sensitivity may be by preserving cell fluidity and rheology, or bringing an aberrant omega3:6 ratio back to a normal range (or preventing aberration in the first place) with no therapeutic benefit beyond that. This is supported by Haugaard et al. who demonstrate a correlation between membrane PUFA content (independent of being omega 3 or 6) but additionally the 3:6 ratio, and insulin sensitivity.[313] Finally; in those who develop insulin resistance from fructose overfeeding, fish oil appears to be ineffective at alleviating the insulin resistance (although it still reduces triglycerides).[314] This lends credence to the notion that fish oil's insulin sensitizing effects are at the level of the cell, as fructose causes insulin resistance at the level of the liver and pancreas.[315]

Another possible mechanism is merely negating the negative effects on some saturated fatty acids on insulin sensitivity. Palmitic acid is known to induce muscular insulin resistance,[316] and polyunsaturated fats (either omega-3 or 6) can reduce the negative effects of palmitic acid.[317]

There is some evidence that suggests fish oil might increase insulin sensitivity, but these studies are isolated and are dependent on pre-existing conditions that hinder insulin sensitivity. Fish oil supplementation does not increase insulin sensitivity or reduce fasting_ glucose (a long-term marker of glucose metabolism). Fish oil can, however, reduce blood glucose acutely.

7.3. Diabetes Risk

There appears to be a reduced risk of diabetes associated with a somewhat normalized omega3:6 ratio.[318][319][320]


Edit8. Fat Mass and Obesity

8.1. Mechanisms

In mice, high doses (15% of diet) of fish oil have been noted to induce CPT-1, Nrf1, and PPAR-α expression in adipose tissue;[321] the latter of which tends to be antiobese when activated[322] and the former the enzyme that mediates carnitine transport into the mitochondria and serves as the rate-limiting step of fat oxidation.[323]

PGC1α has also been noted to be induced in adipose of mice[321] but although activation of PGC1α may increase energy expenditure via UCP2 expression it is possible this is just downstream of PPARα activation as there are similarities in this regard between fish oil and fibrates (pharmaceutical PPARα activators).[324][325]

Beyond that, DHA is thought to be the active ingredient as it is better correlated with weight loss in humans.[326]

Fish oil can technically activate the PPARα receptor to induce mitochondrial biogenesis and increase the metabolic rate. Although this effect is confirmed in rodent models, it requires a high oral dose. Rodent models have been noted to be genetically different when it pertains to PPAR metabolism (see: Conjugated Linoleic Acid).

In studies that assess metabolic rate, it is found to not be significantly influenced (despite increased fat oxidation) in otherwise lean men.[327]

Fish oil does not reliably increase metabolic rate.

There may be antiinflammatoy effects at the level of the adipocyte as evidence by less cytokine secretion under the influence of fish oil fatty acids.[328]

Fish oil may exert a localized anti-inflammatory effect, which could indirectly aid fat metabolism in people characterized by excessive inflammation (ie. those with metabolic syndrome).

8.2. Adipokines

Through these agonisms, fish oil can increase adiponectin secretion from fat cells.[329][330] Surprisingly, though, it seems to take up to 6 weeks for this effect to be physiologically relevant in humans at a dose of 2g fish oil daily.[331] Higher levels of circulating adiponectin are seen with diets higher in fish oil omega-3s.[332]

EPA is more potent at increasing adiponectin relative to DHA, and this increase in mediated mostly through PPARy activation.[333][329] Fish oils can also positively regulate leptin in the same manner.[334]

8.3. Interactions with Carbohydrates

It has been noted that the anti-obese effects of fish oil on body weight gain in high-fat fed rats is reversed in diabetic rats[335] and that inclusion of large amounts of sucrose into the diet reduced the anti-inflammatory and weight loss effects of fish oil.[336]

8.4. Weight Gain

In rats that are fed a high fat obesogenic diet, fish oil ingestion (without exceeding caloric intake) appears to attenuate the rate of fat gain over time when consisting of 20-40% of overall calories[337][338][339][340][341] with some studies using more reasonable doses (1-12%) noted the same result but to a smaller degree, with some indication that DHA was more relevant than EPA.[342] It is not sure if this effect is similar in diabetics, as one study has found an augmentation of weight gain (without measuring fat mass)[335] but appears to still persist in already obese animals who are subject to further weight gain.[343]

In general, high doses of fish oil in rats (to a level impractical for human consumption) are able to reliably reduce weight gain if the rats are concurrently fed an obesogenic diet. This appears to occur to a smaller extent with smaller doses, which may be more relevant to human ingestion.

Fish oil is known to suppress the adipogenic receptor PPARy[344] and its mRNA levels.[345]

8.5. Skeletal Muscle Interactions

Fish oil has been noted to increase the expression of the Carnitine Palmitoyltransferase-1 (CPT-1) enzyme in muscle cells[346] (possible secondary to PPAR activation[347]) and increased both peroxisomal acyl-CoA oxidase and UCP3 expression at very high dietary intake in rats (40% of dietary intake).[337]

Skeletal muscle interactions may mediate fat loss through caloric expenditure.

8.6. Interventions

When looking at survey research, there appears to be an inverse correlation with dietary fish oil intake and obesity rates (suggesting a protective effect)[348] or no significant relation at all.[349]

When looking at interventions, one study in otherwise healthy lean men has noted that replacing 6g of fatty acids with fish oil for 3 weeks resulted in a fat loss of -0.88+/-0.16 (relative to placebo with -0.3 +/- 0.34kg) which was associated with an increase in fat oxidation but not metabolic rate.[327]

Fish oil may increase fat loss in otherwise lean individuals, but further research is needed to confirm this effect.

In obese sedentary persons, 6g of fish oil has failed to outperform 6g of control oil (sunflower) either with or without aerobic exercise although there was evidence of slight synergism with fish oil and exercise.[350] The lack of benefit of fish oil to reduce fat mass in obese persons has been noted elsewhere with insulin resistant women given 2.9g DHA and 1.3g EPA for 24 weeks.[309]

Elsewhere, it has been noted (hyperlipidemics) that the decrease in body fat seen with fish oil supplementation is only significant when paired with exercise with no inherent loss being noted at similar doses[351]

In studies that enforce a caloric restriction, fish oil (2,800mg omega-3) ingestion in obese women is associated with greater losses of body fat and weight (24%) than is control oil (saline) which is thought to be related to higher ketone levels detected in the blood.[326] Some degree of fat loss has also been noted with fish oil when it is paired with the Zone diet (Zone diet alone in this study also effective) while it alone was ineffective.[187]

Fish oil may play a role in reducing fat mass in obese people, but it does not have an inherent fat loss effect. This effect is dependent on other weight loss habits, like exercise or caloric restriction. The effect itself is not very strong.


Edit9. Muscle Mass and Hypertrophy

9.1. Mechanisms

Fish oil supplementation has been noted to augment muscle protein synthesis that is induced by Leucine in both young[352] and old adults.[353]

A possible mechanism is supressing SMAD2 and inducing SMAD7 (noted in renal cells[354] and cardiac cells[355]) which is known to suppress the signalling of Myostatin, as myostatin is depedent on nuclear translocation of SMAD2/3 (complex) and this has been noted to be inhibited with fish oil.[355]

There is no evidence for the interaction of fish oil and myostatin. This relationship has not been assessed directly through studies.

9.2. Muscle Bioenergetics

A very high dose (1g/kg bodyweight; about 28% EPA+DHA content) fish oil in rats shows increased glycogen resynthesis rates and increased glucose oxidation independent of insulin,[356] and 14% increase lactate concentration that was dependent of insulin stimulation. The increased glucose oxidation and uptake may be downstream effects of increasing transcription of AMPK.[357] Activation of AMPK has been noted in other tissues by DHA, such as the intestines[115] and can do so vicariously though adiponectin.[332] This increase in glucose oxidation (possibly by AMPK) was also noted at intakes of 1.8g omega3 (1.1 EPA, 0.7 DHA), which quantified the same glucose oxidation rates despite a 17% lesser AUC for insulin.[358]

Fish oil seems to upregulate mRNA for uncoupling proteins (heat production) in mouse muscle UCP3, brown adipose tissue UCP2, and liver UCP2[325][359] although a drop is seen in white adipose tissue UCP2. Muscle upregulation is seen in bovine as well.[360] Although increased UCP expression is correlated with decreased energy efficiency, a dose of 7.2g fish oil (1.1g EPA, 0.7g DHA) does not significantly impair energy efficiency in otherwise healthy males.[304] This study did note a trend of increasing fat utilization over carbohydrates, however; uncoupling proteins were not measured. This may be a dose issue, as metabolic efficiency is greatly reduced when fish oil is superloaded at 40% of energy intake in rats.[337]

Fish oil (technically, EPA) incubation in muscle cells is associated with a greater ability for the muscle cell to switch from glucose to fat as primary substrate for oxidation, a phenomena known as 'bioenergetic flexibility' of 'metabolic switching'.[361]

9.3. Healing rate and Catabolism

In mice subject to immobilization, fish oil supplementation has been implicated in decreasing the rate of muscle degeneration.[362] However, it also hinders recovery after the fact for a few days via the same pathway.[363]

Some studies in post-surgery situations note increased retention of lean body mass when EPA is added to enteral nutrition.[364][365] Its still under investigation, however, as some studies note no difference.[366]

Fish oil significantly influences glucose and fat metabolism in muscle cells, as well as makes the process more flexible. In moderate doses, fish oil appears to beneficially influence bioenergetics through a combination of nutrient uptake and mitochondrial enzymes. Many of fish oil's anti-diabetic effects can be indirectly linked to increased uptake of glucose into the muscle, as well as increased insulin sensitivity. Preliminary evidence suggests fish oil may increase hypertrophy. This evidence is promising, but limited.

9.4. Health Effects

In mice and over longer periods of time, fish oil can preserve the effects of some hormones (insulin, adiponectin) on muscle cells when normally exposed to an obesogenic diet.[367][332] This may be due to the fish oil component DHA being able to partially reverse the reduction seen in muscle glucose uptake with Palmitic Acid, a saturated fatty acid.[357] Normalizing the phospholipid ratio (independent of fish oil) does seem to increase adiponectin secretion, however.[368] It is not clear whether the means to the end (fish oil) or the end (ratio) are the cause of health benefits seen.

In muscle cells, fish oil can also increase AMPK mRNA levels, particularly the AMPKa2 subset.[357] It has been implicated in doing so in white adipose tissue as well.[119]

High doses of EPA (500mg/kg) have been shown to reduce PPARd and PPARy expression in muscle cells, and interfere with the production of pro-inflammatory TNF-a and IL-6, which lend credence to its anti-inflammatory claims.[119] Increased GLUT4 expression was seen at this dose, although lower doses show only increases in GLUT1 translocation.[369]

Possibly through AMPK, a decreased n6/n3 ratio (more omega 3 relative to omega 6) in muscle cells is associated with increased glucose uptake and better whole-body glucose tolerance independent of mitochondria.[44] The ratio was approximately 0.5:1-1.5:1 (fish oil) relative to 17.5:1-29.7:1 (control), as measured in the cell membrane.[44] The muscle cell membrane seems highly response to dietary changes in omega fatty acid intake[370] and has been associated in vivo with human insulin sensitivity.[371]


Edit10. Immunology and Inflammation

10.1. Circulating Cytokines

Interleukin-2 (IL-2) secretion from lymphocytes has been noted to be reduced when murine splenic cells are incubated with fish oil fatty acids[372] which has been noted to affect persons regardless of disease state (lymphocytes in this study isolated from diabetics and controls[373]). As IL-2 is a cytokine that positively influences T-cell proliferation[374][375] and is a stimulator of TNF-α[376] and IL-1 (alpha and beta)[377] secretion, it is likely the suppression of IL-2 underlies other immunological effects of fish oil supplementation.

Mechanisms are not fully established, as a suppression of IL-2 signalling (assessed by T-cell cycle progression) has been noted with fish oil[378] and a reduction in Diacylglycerol (DAG) and ceramide has been noted,[372] with both of those being positive regulators of T-cell proliferation.[379][380] Although the receptor itself appears unaffected in content,[381] a decreased signalling potential (as assessed by ERK1/2 phosphorylation) has been noted in T-cells incubated with fish oil[382][383][384] which may be related to reduced recruitment of PKC isomers (alpha and epsilon) to the cell membrane;[385] this would result in the immunosuppressive effects of fish oil being dependent on membrane rheology and the omega-3:6 ratio.

3.5g fish oil for 12 weeks (otherwise healthy 50-70yrs) has failed to significantly influence IL-2[386] and failed to influence with 2g daily in persons with isolated hypertriglyceridemia.[387] However, 18g of fish oil (2,754g EPA and 1854mg DHA) daily in otherwise healthy youth has been noted to reduce secretion of IL-2 in stimulated PBMCs by a variable 23-52%[374] and in type II diabetics, IL-2 has been reduced following fish oil supplementation (1,548mg EPA and 338mg DHA for 8 weeks) by 17.1%.[388] The efficacy of fish oil in suppressing T-cell activity and IL-2 does not appear to depend on disease state.

Athletes undergoing exercise given fish oil (6 weeks of 1,300mg EPA and 300mg DHA) have noted an increase in neutrophil (PBMC) produced IL-2 when measured 3 hours post exercise relative to placebo,[389] which due to IL-2 normally being suppressed after exercise[390] this was interpreted as a reduction in immunosuppression. This has been noted elsewhere in elite swimmers,[391]

Interleukin-2 appears to be somewhat unreliably suppressed following supplementation of fish oil, which may be due to the dietary ratio of omega-3 and omega-6. Suppression of IL-2 results from impairing signalling on a T-cell, and the ultimate result is less IL-2, which results in less T-cell proliferation, tumor necrosis factor (TNF-α), and IL-1β.

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine that appears to be negatively correlated with omega-3 status.[392] This cytokine is positively influenced by IL-2 stimulation[376] and a reduction in IL-2 would result in a reduction in TNF-α. Similar to IL-2, the receptors for TNF-α are unaffected following fish oil supplementation[393] but unlike IL-2 the stimulation of TNF-α from a stimulated immune cell (in this case, monocyte) does not appear altered.[394]

Reductions in TNF-α have been noted in otherwise healthy men,[395][191] and youth (offspring of type II diabetics[396] or obese youth[397]) and has been noted with high doses (18g) in young adults[398] and more moderate doses in persons on hemodialysis.[399] However, similar to IL-2 there are several null effects suggesting no change[386][400][401] and the demographics of the positive and negative studies overlap including disease states or medical conditions such as hemodialysis[399][400] and thus it is unlikely that this conditionally works in a certain demographic.

TNF-α concentrations in serum appear to be unreliably reduced following supplementation with fish oil, and due to the high correlation with reductions in IL-2 and TNF-α paired with a plausible mechanism, it is thought that the reductions in TNF-α are due to less circulating IL-2.

C-reactive protein normally is inversely related to serum omega-3 fatty acids[402] or noted to be positively correlated with omega-6 fatty acids.[403]

C-Reactive protein has been noted to be reduced at rest in otherwise healthy men following 6 weeks consumption of 2224mg EPA and 2208mg DHA[395] and women on hormone replacement therapy have experienced a decrease in C-reactive protein with 7-14g fish oil daily (35% and 10.7%, respectively).[404]

1.5g of fish oil, with or without 800mg Vitamin E has failed to reduce C-Reactive protein.[394] In stroke recoverers (65+/-10yrs) given 1.2g fish oil daily, C-reactive protein is unaffected,[405] youth given 0.6g EPA with 0.26g DHA fail to find a reduction,[393] and in persons with mild hypertriglyceridemia it is also unaffected.[406]

C-reactive protein appears to be reduced following ingestion of fish oil, although it is somewhat unreliable. Usually, no significant influence is seen. It is possible that very high doses of fish oil can force a reduction in CRP.

3.5g fish oil for 12 weeks (aged 50-70) has failed to influence IL-6 along with 12 other parameters measured (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 (or CXCL8), IL-10, IL-12p70, IL-13, IFNγ).[386] IL-1β and IL-6 have elsewhere been unaffected in persons on dialysis (2,400mg fish oil[400] and 3,400mg[406]) as well as healthy persons (775mg EPA[401]) but IL-6 has been reported to be decreased in otherwise healthy older men given 1.5-2.5g fish oil daily to a magnitude of 10-12%[191] and in women on hormone replacement therapy with 7-14g fish oil daily.[404]

The levels of IL-6 secretion in response to LPS stimulation have been seen to not be significantly influenced by 7-14g fish oil in postmenopausal women[404] but has been noted to be reduced (14%) in medical students in response to LPS.[407] When assessing neutrophil function, although IL-1β, IL-10, and IL-23 appear to be suppressed (IL-5 and IL-17 trending) IL-6 was not.[401] IL-1 (both subunits) have elsewhere been noted to be reduced with fish oil supplementation.[398]

Other interleukins tend to not be significantly affected, although IL-6 appears to be reduced in some instances. The instances where IL-6 are reduced correlate well with instances where C-reactive proteins are reduced.

10.2. Chemotaxis and Cell Adhesion Factors

Chemotaxis is the process by which immune cells are recruited to a specific site in the body in response to secreted cytokines and involves the immune cell rolling along the endothelium until it attaches to cellular adhesion factors (E-Selectin, ICAM-1, and VCAM-1 being most researched) and is pulled into tissue.[408][409]

The arachidonic acid metabolite known as Leukotriene B4 is a potent chemoattractant (promoting chemotaxis) and it appears that following supplemental fish oil this chemoattractant is reduced and ultimately less chemotaxis occurs for both neutrophils and monocytes in both diseased and healthy populations.[410][411][412][413][398]

There appear to be less chemotaxis associated with fish oil supplementation, which reduces the rate at which immune cells (neutrophils and monocytes) can penetrate tissue. This is an immunosuppressive action, since it lowers levels of the immunosupportive omega-6 fatty acid metabolite (Leukotriene B4) and can reduce immunity and inflammation independent of circulating cytokines.

In animal studies or in vitro, decreased expression of cell adhesion factors have been noted on monocytes,[414] macrophages,[415] lymphocytes,[416] and the endothelium;[417][418][419] This has been noted with both EPA[419] and DHA[418] in isolation.

In human studies, supplemental fish oil is able to reduce the ability of isolated immune cells to express cell adhesion factors in response to immunostimulatory agents when tested outside the body[420][421] and serum levels of soluble adhesion factors have been noted to be decreased[422][419] There appears to be some associated with age, having this immunosuppressive reduction of adhesion factors occuring in elderly persons but not youth[422] but even then it is somewhat unreliable.[386]

Cell adhesion factors are technically reduced by eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Since omega-6 fatty acids confer the opposite effect, it is plausible that increasing the omega 3:6 ratio confers immunosuppression while the reverse confers immunopotentiation.

10.3. Neutrophils

Neutrophil EPA and DHA are both reliably increased following supplementation of fish oil.[423][424][401] Supplementation of EPA in isolation is able to increase DHA levels in neutrophil membranes[401] although very high doses (1600mg) of DHA are required to increase EPA concentration.[424]

The suppression of Leukotriene B4 seen in vitro[425] and following oral ingestion in humans[423][424] appears to be related to a reduced ability of stimulated neutrophils to produce it,[425] which has been confirmed in humans consuming fish oil (31% reduction with 775mg EPA).[401] When looking at genes affected by fish oil ingestion in neutrophils, a decrease in protein content of PI3Kα and mRNA content of PI3Kγ (PI3Kβ and PI3Kδ unchanged) has been noted and the reduction in signalling via Akt/NF-kB thought to play a role.[401]

Fish oil supplementation, due to the interaction of fish oil fatty acids and the neutrophil membrane, appears to reduce the ability of neutrophils to secrete the pro-inflammatory leukotriene B4. This may be related to the suppression of phosphoinositide 3-kinase (PI3K)/Akt.

In regards to oxidative function (neutrophils use oxidation to destroy pathogens via a process known as oxidative burst,[426] mediated by NADPH[427]) superoxide production appears to be increased following fish oil ingestion at 2g daily (300mg EPA and 400mg DHA)[428]

2g fish oil (300mg EPA, 400mg DHA) daily in cancer patients for 8 weeks reversed the chemotherapy-induced reduction in neutrophil count and phagocytosis (neutropenia[429]) to a 29% increase (all PMBCs) and 14% increase respectively; superoxide production of neutrophils was enhanced 28%.[428]

10.4. Monocytes and Macrophages

Monocytic secretion of IL-1β, IL-6, and TNF-α appears unaffected (MCP-1 activation) following ingestion of fish oil at the dose of 1,500mg daily for 12 weeks with or without 800mg Vitamin E.[394]

3 weeks of 4g fish oil has failed to significantly influence parameters of monocytic activation or adhesion in healthy persons and those with coronary artery disease.[289]

10.5. Natural Killer Cells

Natural Killer (NK) Cells are immune cells that aim to induce cellular death, and are important in cancer prevention. Fish oils at 10% of the diet by weight in rats are able to preserve NK levels closer to pre-operation levels than when compared to a normal feed diet, with no apparent effect in pre-operation (healthy) levels.[430]

At rest in older individuals (55yr or above), supplemental fish oil (720mg EPA, 280mg DHA) for 12 weeks has noted a 48% reduction in NK cell activity which was not replicated by supplemental DHA (720mg) or other tested fatty acids (arachidonic acid, GLA, alpha-linolenic acid)[431] despite other studies noting that supplemental DHA may reduce NK cell activity in young men (albeit at 6,000mg daily)[432] and EPA between 1,350-4,150mg daily for 12 weeks in youth failed to note an increase.[433]

NK cell activity has been found to be enhanced in otherwise healthy young men subject to exercise (accreddited to an increase in NK cell content that was induced by exercise[389]) which is thought to be due to decreasing PGE(2) concentrations which naturally retard NK cell activity.[434] An increase in IL-2 was also noted,[389] which is known to stimulate NK cell activity.[435]

There is currently mixed evidence as to the role of fish oil supplementation on Natural Killer (NK) cell activity, with both increases and decreases observed. Further research is needed to determine the cause of the discrepancies.

10.6. B-Cells

B cells are a subset of lymphocytes with prominent effects in lung and intestinal tissue that serve to secrete antibodies and some cytokines to act as support cells in defense against pathogens.[436][437] B-cells have been confirmed to incorporate fish oil lipids into their membranes ex vivo[438] and following oral ingestion.[439] It is thought that the mechanism by which fish oil acts is via supporting formation of lipid rafts.[439][440]

Mice ingesting fish oil (12-14.5% of diet by calories) appear to have increased CD69[438] and CD40[439] receptor expression with no influence on CD80, CD86, nor MHCII;[439] B-cell secretion of IFNγ and IL-6 appears to be enhanced up to 50% ex vivo when stimulated by LPS[439] and has been noted to occur in vivo.[438][440] The response of B-cells to antigens appears to not be significantly influenced,[439] yet higher IgA concentrations have been detected in mice.[440]

In humans, studies have failed to find alterations in serum concentration of B cells (not activation thereof) with doses of DHA ranging from 720mg to 6,000mg.[431][432][433]

Supplementation of fish oil has not been found to alter the concentration of B-cells in the body, and the binding of B-cells to antigens appear to be unaltered. However, the B-cell appears to be more responsive to inflammatory stimuli and may secrete more antibodies, which would suggests fish oil may enhance adaptive immunity.

B-cell activation may underlie increases in serum interleukin 6 (IL-6) and interferon gamma (IFNγ).

10.7. T Cells

T cells are lymphocytes that can be divided into helper T cells (depending on whether they express the receptor known as CD4, in which case they are referred to as CD4 positive) and cytotoxic T cells (same idea but with a receptor known as CD8). CD4+ and CD8+ are shorthand for helper and cytotoxic T cells, respectively.

CD4+ T-cell activation occurs when T cells are met with antigen presenting cells (dendritic cells) and is mediated by receptors (TCRξ/CD3) and costimulators (ICOS and CD28 as positive modulators, CTLA-4 and CD152 as negative).[441] It appears that the signalling cascade that results in expression of the T-cell receptor (TCR) is suppressed when fish oils are incorporated into the cell membrane[442][443][444] and the ultimate result is less associated with T-cells and dendritic cells and an immunosuppressive effect[445][446] which has been confirmed in mice at 1.5% of the diet as omega-3[447] or 200mg/kg.[446]

Incorporation of fish oil fatty acids into the T cell membrane appears to be associated with fewer dendritic cells, and thus less activation.

When looking at human interventions fish oil supplementation has repeatedly failed to negatively influence T-cell function with 4,050mg EPA for 12 weeks in young and middle aged men,[433] 6,000mg of DHA for 90 days,[432] or their combination at 720mg EPA and 280mg DHA.[431] However, one trial in healthy older adults with similar doses as before (720mg EPA and 280mg DHA) has noted a suppressive effect associated with EPA (and the omega-6 fatty acid GLA) but not DHA.[448] This suppressive effect was partially reversed 4 weeks after supplement cessation.[448]

Interestingly, dietary alpha-linolenic acid (parent omega-3 fatty acid) has been reported to reduce the rate of lymphocyte proliferation at 18g a day[449] and in vitro arachidonic acid has also shown immunosuppressive effects on lymphocyte proliferation.[450][451] It is possible that overall polyunsaturated fatty acids play a role (it has been noted elsewhere that T cell suppression is abolished not by COX/LOX inhibitors (eicosanoids) but by lipid antioxidants[452]), although this does not explain the lack of efficacy of DHA in the same study that noted EPA was immunosuppressive.[448]

There is mixed evidence as to whether fish oil related immunosuppression is a concern in otherwise healthy people. It is possible that the interaction of fish oil and T lymphocytes is related more to total membrane polyunsaturated fatty acid (PUFA) content than it is to the omega 3:6 ratio, but this claim requires further research.


Edit11. Interactions with Oxidation

11.1. Lipid Peroxidation

Fish oil EPA and DHA are both polyunsaturated fatty acids, and each unsaturated bond (double bond) can possibly be oxidized; this would convert the lipid itself into an oxidant capable of producting other oxidants[453][454][455] and is a phenomena common to any unsaturated fatty acid including arachidonic acid.[456] Although this is sometimes required for bioactivity (first stage in eicosanoid production from DHA requires a free radical), it is desirable to avoid fish oil oxidation ex vivo (prior to supplementation) and is a reason why Vitamin E (reference lipid antioxidant) is almost always included alongside fish oil products (with somewhat lacklustre results, actually[457]).

Lipid peroxidation can be measured in the blood by either TBARS,[458] Malondialdehyde (MDA),[459] 4-hydroxy-2-nonenal,[460] or oxidative metabolites of eicosanoids (notable 8-iso-PGF2α);[461] sometimes serum Vitamin E is also measured, and a decline is thought to be due to being sacrified to prevent lipid peroxidation. Of these measurements, MDA and 4-hydroxy-2-nonenal may be more reliable as 8-iso-PGF2α has been noted to be decreased in the urine following fish oil consumption[462][463][464] (indicative of antioxidant effects) and fatty acids such as Conjugated Linoleic Acid (CLA) have been noted to interact with 8-iso-PGF2α indepedent of oxidation before.

Polyunsaturated fatty acids can be oxidized to form lipid peroxides, which can produce a variety of intermediates, like 4-hydroxy-2-nonenal and malondialdehyde. These intermediates are pro-oxidative.

8g of fish oil (1,600mg EPA+DHA) that has already been oxidized prior to consumption in otherwise healthy subjects for 7 weeks has failed to show evidence for lipid peroxidation (Vitamin E, isoprostane, and hydroxy-nonenal measurements)[465] and makes note of other studies using nonoxidized fish oil failing to find an increase of urinary isoprostane or serum biomarkers (MDA) following fish oil consumption[466][462][467] which seems to be the consensus.[468]

When selectively looking at evidence that does support a change, the direction is mixed; some studies have reported increases in 4-hydroxy-2-nonenal following DHA consumption in humans[469] and the combination of fish oil and exercise (although quelled with Vitamin E)[470][471][472] and may increase lipid peroxidation in animals via TBARS.[473]

There is currently weak evidence to support an increase in lipid peroxidation following fish oil consumption (even if it is oxidized prior to ingestion). There is ample evidence to suggest such an increase does not occur in otherwise healthy adults.

DNA damage can easily be induced by oxidative stress and lipid peroxides are capable of damaging DNA,[474] and is a mechanism by which oxidation and cancer risk are linked (with inducing damage to DNA being negative).[475]

Studies in research animals that measure DNA damage note less damage with fish oil supplementation relative to safflower oil as reference[476][477] (assessed by urinary 8-oxo-7,8-dihydroguanine[478]) and fail to find induced damage with intakes up to 3,305 and 3,679mg/kg isolated DHA in otherwise healthy rats (male and female respectively; human equivlance of 529mg/kg and 588mg/kg)[479] although DHA has been noted to increase DNA damage in older rats at 300mg/kg.[480] One study that confirmed an increase in urinary 8-oxo-7,8-dihydroguanine with a normalized omega-3:6 ratio (relative to high omega-6) also noted enhanced DNA repair enzymes[481]

Human evidence suggests (epidemiology) that higher serum omega-3 fatty acids are associated with higher rates of DNA damage relative to higher omega-6 fatty acids[482] but interventions have found no significant influence on DNA fragmentation during a marathon race,[483] and during pregnancy.[484]

It is theoretically possible that high doses of fish oil (lowest dose noted being 300mg/kg in rats or 48mg/kg DHA in humans) in a susceptible population, such as elderly people, can enhance the rates of DNA damage, but it is not known how relevant this is to supplementation, since enhanced DNA repair was also noted. Based on human evidence, fish oil supplementation causing DNA damage does not appear to be a concern.

11.2. Antioxidant Enzymes

In regards to human studies that measure antioxidant enzymes (notably glutathione peroxidase, catalase, and superoxide dismutase) there do not appear to be significant changes in either a protective nor harmful manner[465][485][486] although limited evidence suggest a small (likely not clinically relevant) increase in glutathione in overweight women.[487] An increase has been noted in rodent studies when investigating populations that normally have suppressed glutathione (the increase thought to be secondary to preservation of glutathione[488][489]) but human evidence does not yet replicate this.

Although increases in antioxidant enzymes have been noted sporadically, there is likely no significant effect of fish oil supplementation on the most commonly measured parameters.


Edit12. Exercise and Performance

12.1. VO2 Max and Oxygen Consumption

Studies that have failed to find a significant influence of fish oil consumption on VO2 max include 3,000mg fish oil (1,300mg EPA; 300mg DHA) for 6 weeks.[389]

12.2. Exercise-related Immune Suppression

In response to exercise in trained men, high dose fish oil (2224mg EPA and 2208mg DHA) for 6 weeks was able to reduce inflammatory cytokines (CRP and TNF-α) at rest but failed to alter the exercise-induced changes in immune parameters.[395]

Natural Killer cells appear to have enhanced cytotoxicity for 2 hours after exercise (afterwards they return to baseline)[490][491] and 3,000mg of fish oil (1,300mg EPA and 300mg DHA) daily for 6 weeks in otherwise healthy men is able to augment the exercise-induced increase in NK cell activity alongside an increase in IL-2 (no changes in IL-4, IL-6, cortisol, or IFN-γ).[389] This is somewhat different than other anti-inflammatories, as indomethacin has been noted to abolish NK cell activity from exercise[491] and is thought to be due to increasing NK cell count rather than individual activity (as no evidence for increased activity was noted when cellular concentration was controlled for).[389] Possible explanations for this include an increase in IL-2 (noted[389] and known to stimulate NK cell activity[435]) and a reduction in PGE(2) concentrations, which would be attenuating a negative regulator of NK cell activity.[434]

Preliminary evidence suggests that fish oil can augment the natural killer cell (NK) cytotoxic response to exercise, but due to the variability seen with natural killer cells in general, it is not known how reliable this effect is.


Edit13. Pregnancy and Lactation

Note: Any intervention for increasing fish oil consumption during pregnancy must be met with an accompanying avoidance of mercury, as infants appear to be at high risk for cognitive impairment from excessive mercury consumption (relative to adults). Advice on avoiding mercury can be found in the first section of this article.

13.1. Benefits to Mothers

It is thought that supplemental fish oil can benefit the mothers due to the fetus sequestering EPA and DHA for development, which is thought to underlie the reduction in plasma EPA and DHA seen in pregnant women.[492]

One study in pregnant women who also had major depressive disorder found that 2,200mg EPA and 1,800mg DHA was able to reduce depressive symptoms during the perinatal period and postpartum[168] although to counter this intervention is a fairly large amount of trials using a range of EPA or DHA supplementation reporting null effects.[493][494][164][165][166][167] It is possible that fish oil merely acts in pregnant women the same as in all depressed persons (EPA being more anti-depressive in persons with worse depression) and that perinatal and postpartum related depression that is not to the magnitude seen in major depressive disorder is unaffected.

Fish oil, particularly eicosapentaenoic acid (EPA), does not appear to have any special effects in regard to depression associated with the perinatal and postpartum period. EPA is antidepressive in the most depressed cohorts. This has also been noted in pregnant women, who also had major depressive disorder. Many trials with depression of a lesser magntiude have reported a failure of fish oil to benefit depression.

Gestational diabetes is a transient state of diabetes occurring in 3-8% of pregnancies[495] with mixed survey evidence as to whether dietary fat from fish is associated with gestational diabetes risk.[496][497][498]

800mg DHA daily in pregnant women has failed to significantly alter risk for gestational diabetes.[499]

Fish oil does not appear to significantly reduce the risk of gestational diabetes.

Pre-eclampsia is a pregnancy complication associated with vasoconstriction and endothelial damage, and its pathology appears to involve prostaglandins.[500][501] One meta-analysis[502] has claimed insufficient evidence to support an effect of fish oil (using mostly underpowered studies) and a more robust trial of 2399 women has failed to find a protective effect with 800mg DHA supplementation (1.5g omega-3).[499]

There is insufficient evidence to support fish oil's role in reducing the risk of pre-eclampsia.

13.2. Birth

There may be less death in infants associated with maternal DHA consumption, with one study noting that while control experienced 12 and 5 neonatal deaths and convulsions (respectively) 800mg DHA reduced this to 3 and 0.[499] This trial stated that further research is needed.

Infant weight has been noted to be increased with supplemental fish oil to a moderate degree (47g, 95% CI of 1-93g) and a slightly increased time to birth (2.55 days; 95% CI of 1.03-4.07 days), but despite the increased time to birth this analysis only found a protective effect against premature birth when measuring before 34 weeks (no effect at 37 weeks).[502] This increased time until birth resulting in greater infant weight has been noted elsewhere with 2,700mg fish oil.[503]

Fish oil may reduce the risk of birth complications and the risk of premature birth (relative to not consuming any omega-3 fatty acids), with a moderate amount of evidence to support increased birth weights and prolonged time to birth. Very preliminary evidence suggests fish oil supplementation can reduce the risk of neonate death.

13.3. Pregnancy Consumption and Benefit to Offspring

Consumption of omega-3 fatty acids (or any polyunsatuated fatty acid) is known to cross the placental barrier[504][505] via FATP transporters (particularly FATP4)[506] to regulate nervous system development.[507] Unlike adults, the fetus in not capable of inherently synthesizing sufficient omega-3 fatty acids and thus parental provision is mandatory[507] and supplemental DHA has been confirmed (in primates) to be approximately 8-22 times more effective at increasing neural DHA stores in offspring than the parent omega-3 fatty acid (ALA).[508] It should be noted that arachidonic acid (omega-6 counterpart to EPA) is also vital for cognitive development, but seems to be less responsive to the diet suggestive of better regulation.[509]

Docosahexaenoic acid (DHA) plays a critical role in the neural development of the fetus during pregnancy. The fetus depends on parental provision of DHA, either through supplementation or the diet. It is for these reasons that supplemental fish oil is thought to increase cognitive development in unborn children, but it is unknown if the omega 3:6 ratio plays any role here, as arachidonic acid is also critical.

One review and meta-analysis (11 trials reviewed with a sample of 5272; 7 in meta-analysis) has been conducted assessing cognitive and visual performance of offspring of mothers who consumed omega-3 fatty acids during pregnancy[510] assessing the following trials[511][512][513][514][515][494][516][517][518] (two not found online) noted that no significant effect of fish oil on cognitive capacity could be reliably determined while the one statistically significant benefit on Developmental Standard Scores (3.92; 95% CI of 0.77-7.08) had a high risk for bias.[510] The bias mentioned in the review to be of most concern were high attrition rates (27–86%) and unclear and haphazardous randomization while publication bias could not be ruled out due to some studies not being fully published (but similar null results being reported in the abstracts).[510]

Further study is needed to determine the effects of maternal fish oil supplementation on the cognitive development of offspring. Although a benefit cannot be ruled out, current evidence does not support any beneficial effects.

13.4. Lactation

Dietary DHA intake is critical during the first three months of life, where it correlates greatly with neural DHA levels (as assessed by autopsy reports)[519][509][520] and due to this importance it is a mandatory additive to baby formulation[509] and provision to preterm infants highly recommended.[521] DHA is also a component of breast milk (and thus provided during breast feeding)[522] of which the concentration of DHA in breast milk is correlated with the mother's diet.[523][524][525]

Supplemental ALA (from flaxseed or plant sources of omega-3) is ineffective in raising breast milk concentrations of DHA, despite an increase in breast milk concentrations of ALA.[526]

It is critical for infants to consume docosahexaenoic acid (DHA) during their first few months of life in order to support cognitive development. DHA is found normally in breast milk, and is a mandatory additive to any infant dietary formulas.

Maternal intake of salmon (3.45g of fish oil per week) during the 20 weeks of pregnancy prior to birth is sufficient to increase breast milk concentrations of EPA (80%) and DHA (90%) when the mothers normally did not consume fish.[527] Increase in breast milk have been noted with supplementation as well during both pregnancy[528][529] and during lactation exclusively[530] or both;[531] with some manner of dose-dependence being noted and highest levels being reached after 2 weeks supplementation.[530][531][528][529] Daily intake does not appear required, as supplementing fish oil (or consuming fish) repeatedly and then ceasing for 2-4 weeks does not normalize breast milk concentrations of EPA/DHA although a decline does appear present.[527][532][533][534]

One study (salmon twice weekly, giving 3.45g fish oil) has noted a reduction in breast milk IgA concentrations.[527]

Breast milk DHA concentrations reflect dietary DHA concentration. Both fish intake and supplementation can elevate levels of breast milk DHA. Supplementation does not appear to be required, as up to 90% increases have been detected with 3.45g of fish oil per week (via salmon consumption). Daily ingestion of fish oil supplements or fish products does not appear to be required.


Edit14. Interactions with Organ Systems

14.1. Eyes

Omega-3 fatty acids, particularly DHA, are known to be highly involved as modulators of retinal capillary integrity, neovascularization and inflammation[535] related to their protectins and resolvins.[85]

DHA has been noted to be decreased in the retina of diabetic rodents[536][537] (as well as plasma of humans[538]), and dietary provision of fish oil (5% of diet totalling 10.26% DHA and 14.16% EPA) is able to abolish the increase in angiogenesis and grealty attenuate inflammatory biomarkers in type II diabetic rats (relative to soybean oil)[539] as well as type I.[540] This protection actually seems to extend beyond diabetes (being noted in a mouse model of retinopathy of prematurity at 2% of the diet[541]) and seems to be related to increased eicosanoids (Neuroprotectin D1 and Resolvin E1/D1 being detected[541]) and a normalized omega3:6 ratio, as the Fat-1 mouse line (genetically altered to normalize the ratio) appears to have reduced risk of angiopathy.[542]

The increase of acid sphingomyelin (ASM) is also fully normalized relative to omega-6 (soybean) controls[539][540] and is thought to be involved in the pathology of retinal angiogenesis.[539]

Normalizing the omega 3:6 ratio appears to be very protective against retinal angiogenesis. DHA is also important in this protection. In rodents, this protection is nearly absolute during a reasonable intake of dietary fish oil. This means people supplementing fish oil will most likely experience a similar effect.

14.2. Pancreas

Eicosanoids derived from arachidonic acid (AA) appear to be involved in the destruction of pancreatic β-cell (insulin producing cells of the pancreas[543][544]) population,[545] with the PGE2 produced from COX enzymatic activity being most relevant[544][546][547] and related to COX2 specifically.[548][549] COX2 is overexpressed in pancreatic β-cell due to transcription factor NF-IL6,[549] and its increased activity by the cytokine IL-1β appears to link overall inflammation and PGE2.[550]

When PGE2 is elevated in a pancreatic cell, insulin secretion is suppressed[547][551] and proliferation of β-cells are suppressed.[552]

12-HETE (catabolite of arachidonic acid) is detected in pancreatic cells[553] and appears to also contribute to β-cell toxicity via NADPH oxidase-1 dependent mechanisms following conversion by 12-LOX (also expressed in pancreatic cells[553])[554] yet does not suppress insulin secretion[555] like similar structures (5-HPETE[556] and both LTB4 and 15-HETE[555]); although dietary inclusion of omega-3 fatty acids can reduce the arachidonic acid metabolite LTB4,[423][401][424] results in humans investigating 5-HETE suggest no suppression.[423]

There is limited evidence to draw connections between the above mechanisms and supplemental fish oil. One study in Fat-1 mice (with a normalized omega3:6 ratio) noted more protection against inflammation induced cell death[557] and seem to be resistant to the pancreatic toxin streptozotocin.[558]

There is no human evidence to suggest a link between fish oil consumption and improved pancreatic cell functioning. This relationship appears to be plausible in mouse models, where it has been observed.

14.3. Kidneys

Fish oil supplementation beneficially effects kidney function in those with diabetes (and at risk for diabetic nephropathy) at 4g daily,[559] whereas animal models with higher doses show more dramatic protection.[560] The mechanism may be through reducing pro-inflammatory cytokines in the kidney and through eicosanoid production.[561][562] There isn't the largest body of literature on this function exclusively, and at least one recent review suggests that a final conclusion on fish oil's effects on renal function is preliminary.[563]

There have been correlations established between dietary PUFA (Polyunsaturated fat) intake of omega3s and prevention of renal disease, suggesting a preventative role may also exist.[319]

Omega-3 supplementation may play a protective role in the development of renal pathology associated with diabetes.


Edit15. Interactions with Cancer Metabolism

15.1. Skin

High intake of dietary fish products are associated with reduced risk of skin cancer[564][565] (while higher omega-6 intake is associated with increased risk[566]) which is thought to be related to reduced sunlight-induced immunosuppression (noted in rats[567] and humans with 4,000mg EPA+DHA[568]) resulting in reduced tumor multiplicity and increased tumor latency.[569][570][571]

The mechanisms are thought to be related to membrane fatty acid content (and due to that, eicosanoid and prostaglandin signalling) as EPA is known to compete with arachidonic acid in the membrane[572] and higher dietary intakes of omega-6 in research animals augment solar radiation induced skin carcinogenesis secondary to immunosuppression.[567][573][569]

Fish oil supplementation, and specifically the omega 3:6 ratio in skin membranes, appears to have a protective mechanism in regard to skin cancer. The links between fish oil and skin cancer development are related to immunity, with higher fish oil intake reducing the immunosuppression induced by sunlight.

15.2. Pancreas

In pancreatic cancer cells, both EPA and DHA induce apoptosis (not inhibited by COX inhibitors) via inducing reactive oxygen species and subsequent autophagy at a concentration of 10mM, which was abolished (in vitro) with the addition of Vitamin E; when mice are injected with pancreatic tumors (MIA-PaCa-2 cell line) and fed 5% of the diet as fish oil, it appears that fish oil was associated with a reduction of tumor volume to approximatley a third of control.[574]


Edit16. Interactions with Disease States

16.1. Lupus erythematosus

Lupus erythematosus (Lupus) is a disease state characterized by arthritis, vasculitis, rash, and the involvement of the central nervous system that appears to be associated with reduced omega-3 (EPA and ALA) and GLA content in lipid membranes.[452] Fish oil is investigated for treatment of lupus as the first pilot study in humans noted full remission from symptoms associated with mixed EPA/DHA supplementation for 8 months or more (162mg EPA and 144mg DHA).[452]

Other studies note that 3g of omega-3 fatty acids from fish oil[575] or EPA in isolation[576] in patients with lupus (for up to 24 weeks of supplementation) appears to reduce general symptoms as assessed by the rating scales of SLAM-R (33-34% reduction[576][575]), BILAG (51% reduction[575]), and may benefit blood flow as assessed by flow-mediated vasodilation[575] and has mixed effects (55% of patients) on treating dyslipoproteinemia.[577] In rats, the progression of nephtritis is attenuated with fish oil supplementation which promotes lifespan[578][579] and this effect has been noted in humans (15g for 1 year) to a much lesser degree, where proteinuria is reduced nonsignificantly and glomerular filtration rate is unaffected.[580]

There is some counter evidence, with at least one study noting that the benefits observed at 3 months was no longer present at 6 months (200mg/kg bodyweight at 18.6% EPA and 12.1% DHA)[581] and benefit has been noted with superloading elsewhere (20g daily for 12 weeks; study did not proceed towards the 6 month timeframe).[582] Interestingly, the lone other study to use a prolonged high dose intervention (15g daily for 1 year) also noted lacklustre results in renal symptoms of lupus.[580]

Fish oil supplementation appears to play a role in controlling the symptoms associated with lupus, but there is evidence to believe that long term dosing of high levels of fish oil eventually abrogates the benefit and that lower doses (the standard 180mg EPA and 120mg DHA dosage) may be more beneficial.

Since gamma-Linolenic acid (GLA) and dihomo-y-linolenic acid(DGLA) appear to be associated with symptoms of lupus, it is plausible that the omega 3:6 ratio in lipid membranes is important, and that high doses skew the ratio too severely in favor of omega-3.


Edit17. Interactions with Aesthetics

17.1. Skin

Dietary intake of EPA is known to increase skin levels of EPA following ingestion of 10g fish oil (1,800mg EPA and 1,200mg DHA[583]), 4g fish oil (95% EPA ethyl esters)[584] and 10g fish oil (1,800mg EPA and 1,200mg DHA).[583]

Solar radiation is known to transiently suppress the immune system[585] in a dose-depedent manner[586][587] and persons with contact dermatitis (a topical allergic reaction) can be used as research models to assess photoimmunosuppression.[588] Using this model, 5g fish oil (3,500mg EPA and 500mg DHA) has been demonstrated to reduce photoimmunosuppression by 6.9-11%.[568]

Sunlight induced erythema (reddenning) appears to be reduced following supplement ingestion for 3 months or so, with the time of exposure required to induce erythema increaasing 37-117%.[584][583] A reduced sensitivity to sunburns has also been reported.[584]

Fish oil appears to protect the skin against sunlight, with benefits during sunlight-induced immunosuppression as well as sunlight-induced reddening (erythema). A reduced risk of burns has been reported to be associated with fish oil consumption. These mechanisms appear to be sensitive to the omega 3:6 ratio.

There are mixed reports on how oxidation is influenced in the skin following fish oil consumption, with one reporting no alterations in DNA damage per se but reduced sunlight-induced DNA damage[584] while elsewhere lipid peroxidation (TBARS) has been noted to be increased in skin tissue.[583]

It is possible that fish oil supplementation can increase lipid peroxidation in the skin, but this has not yet been linked to adverse toxicological effects, like as DNA damage. These effects are reduced following exposure to sunlight and fish oil, relative to sunlight alone.

Fish oil was first thought to reduce pressure ulcers in critically ill persons in a study that was confounded with GLA and antioxidants[589] where the benefit was thought to be due to improved blood flow noted with this combination therapy[590] or changes in immunity;[591] fish oil in isolation has been noted to confer these properties by reducing pressure ulcer formation by 20-25%[592] although this study has been criticized for its lack of data.[593]

It is theoretically possible that fish oil supplementation can reduce pressure ulcer formation in the critically ill, but this claim lacks a strong evidence and requires further investigation.

17.2. Hair

There is a surprisingly lack of literature investigating the link between fish oil and hair, despite the knowledge that prostaglandins are involved in hair growth regulation.[594] The machinery appears to be present, as phospholipase A2 has been detected in hair follicles on the outermost epithelium[595] and receptors for PGE(2) (EP3 and EP4) have been detected on the dermal papillae.[596][597] Drugs that act like PGE2 and PGE2α (Viprostol and Latanoprost) have been noted to induce hair growth[598][599] associated with promotion of hair follicles to anagen phase[600] while COX2 overexpression induces hair loss (restored with COX2 inhibitors[601][602]); both overexpressing and abolishing phospholipase A2 activity reduces hair growth.[595]

Both PGE2 and PGE2α have been found to be produced locally in hair cells[594] and theoretically can induce hair growth via their receptors (EP3 and EP4), although all prostaglandin receptors appear to be expressed in various areas of the hair follicle.[603]

There is furthermore a plausible link between prostaglandin receptors and androgen metabolism, via the receptors that respond to both classes of molecules (AKR1C1 to a lesser degree, and both CBR1 and AKR1C3[604] are expressed in hair follicles[594]); PGE(2) may not increase testosterone per se, however.[605] Additionally, the enzyme known as prostaglandin D2 synthase (which converts Arachidonic acid metabolite PGH2 to PGD2) is known to be induced by androgenic signalling[606][607] and the higher PGD2 is correlated with and has a causative role in suppressing hair growth in man;[608] EPA has been noted to suppress PGD2 in mast cells (immune cells) by competing with arachidonic acid at the COX enzymes[609] and has been noted to suppress PGD2 elsewhere in macrophages.[610]

Prostaglandin E2 (PGE2) production from eicosanoids appears to be a positive modulator of hair growth, while inflammation appears to negatively influence hair growth via prostaglandins (and COX2). The connection between this relationship and fish oil supplementation is not known at this time.

Supplemental polyunsaturated fats to dogs (9.3g linoleic acid with either 3.3g or 0.42g of ALA per 1000kcal) has been noted to increase hair softness and glossiness but also greasiness and scaliness, which was thought to be associated with increased cholesterol esters found in hair cells.[611] This has been noted elsewhere, again in dogs.[612]

Further study is needed to determine the effects of fish oil supplementation on hair.


Edit18. Nutrient-Nutrient Interactions

18.1. Uridine

In cellular membranes phosphatide subunits bind to fatty acids, uridine, choline, and some other molecules such as amino acids to form the components of the membrane.[613] Uridine is important in the body as it confers a pool of substrate[197][614] to make the molecule Cytidine-5'-triphosphate, the availability of which is the rate-limiting step[615] in transfering a Cytidine monophosphate from Cytidine-5'-triphosphate to phosphocholine, which would result in the production of CDP-choline. As CDP-choline highly interacts with DHA to form Phosphatidylcholine phospholipids in membranes,[616] supplemental Uridine (via CDP-choline) is thought to be synergistic.

Uridine provision is the rate limiting step in the body when producing phosphatidylcholine (via CDP-choline), associated with docosahexaenoic acid (DHA). Provision of uridine accelerates production.

Ingestion of choline, uridine, and DHA (constituents of phosphatidylcholine synthesis) in rats appears to increased brain membrane concentrations of phosphatidylcholine by 50% or more[241] and appears to be synergistic as any agent alone increased phosphatidylcholine by 13-22% in this study where combination of all increased PC concentration by 45%.[617] This positive influence on brain phospholipids also applies to other phosphatamides such as phosphatidylethanolamine, phosphatidylinositol, and Phosphatidylserine[617][242] and while DHA is less effective than combination therapy uridine in isolation tends to be inactive which rules out mere additive effects.[242]

Uridine and docosahexaenoic acid (DHA) appear to be synergistic in increasing phospholipid concentrations in the brain of research animals (uridine augments DHA's ability to increase). There may be further synergism with choline. This suggests potency between Krill Oil, which is DHA complexed, Phosphatidylcholine, and Uridine supplementation.

Combination therapy with DHA (300mg/kg) and Uridine as 5’-monophosphate (0.5%) has been found to increase dendritic spine density (36%) in the adult gerbil hippocampus over 4 weeks; combination therapy appeared to be more effective than DHA alone (18%) and since uridine was inactive in isolation it appeared to be synergistic.[242] There was no influence on spine size, only density.[242]

Uridine has been implicated in augmenting dendritic spine density in the hippocampus, induced by docosahexaenoic acid (DHA) provision, which is thought to underlie possible synergism in memory enhancement.

18.2. Linoleic Acid (Omega-6)

Linoleic acid (LA) is the parent omega-6 fatty acid, which is bioconverted into arachidonic acid in the body and tends to antagonize the effects of fish oil supplementation.

One study that measured the triglyceride lowering effects of fish oil noted that while fish oil (3.1g daily) reduced triglycerides by 51% when paired with a low LA food product, but by increasing linoleic acid by 7.3g per day with a high LA food product the reduction in triglycerides was attenuated to 19%.[618] This possibly extends to food consumption as well, with fish having a higher omega 6:3 ratio having less benefits to artherogenesis (plaque in arteries) than do a similar amount of omega-3 with less omega-6.[619]

The effects of fish oil on immune cells may not be affected by linoleic acid consumption.[620]

The parent omega-6 fatty acid may antagonize the triglyceride-lowering effects of fish oil, even when supplemented or eaten. If fish oil is being used for that purpose, coingesting the two is not advised.

18.3. Astaxanthin

Astaxanthin is a carotenoid that serves as a lipid antioxidant, and is thought to in part contribute to the health benefits of consuming red fish (salmon) or Krill Oil.

A decrease in proliferative capacity of lymphocytes has been noted with fish oil (17mg/kg bodyweight) paired with astaxanthin (1mg/kg) which is thought to be either additive or synergistic since no reduction was seen with either agent alone;[621] said reductions have indeed been noted with astaxanthin (5µM[622]) and with PUFAs elsewhere,[623] but in higher concentrations/dosages.

18.4. Curcumin

Curcumin is the main bioactive of the curcuminoids derived from some spices (usually Turmeric but with a small content in Ginger).

The combination of DHA and Curcmin in isolated breast cancer cells (MDA-MB-231, MCF-7, and three others) appears to be synergistically antiproliferative, where although 30μM of either compound in isolation failed to act the combination (18μM DHA and 12μM curcumin) suppressed proliferation.[624] There was less genomic activity with the combination than with isolated curcumin, and proteins that were unaffected by either compound in isolation but affected by the combination include CXCR4 (suppressed), aromatase (induced), SERPINB5 (suppressed), PPARγ, and p53 phosphorylation.[624]

Fish oil and curcumin appear to be synergistic in suppressing breast cancer cell proliferation, which is associated with inducing some proteins not seen with either isolated compound.

There may be synergistic anti-inflammatory effects in macrophages with curcumin and both fish oil fatty acids as assessed by LPS-induced PGE(2) production[625] and in a rat model of colitis (inflammatory bowel disorder) curcumin and fish oil have been noted to be synergistic.[626]

Brain derived neurotrophic factor (BDNF) is a protein that positively regulates synaptic growth and neuronal growth[627] and due to its positive influence on long term potentiation and synaptic growth[628] it is thought to be a molecular target of cognitive enhancement.

DHA is known to support neuronal membrane fluidity[629] and increase BDNF concentrations[630] and DHA (1.25% of diet) has been noted to augment the BDNF-induced learning that occurs from exercise in rats.[630] Due to the synergism present with DHA and exercise and the ability of curcumin to also support BDNF levels[631] it has been hypothesized that they are synergistic.[632]

Theoretically, curcumin may be synergistic with fish oil in increasing brain-derived neurotrophic facto (BDNF), and thus learning. This effect has not been demonstrated in practice.

18.5. Fucoxanthin

The carotenoid from seaweed, Fucoxanthin, has been found to be slightly synergistic with fish oil for attenuating weight gain in obese and diabetic mice.[633] The addition of fish oil at 6.9% of the diet (quite a high dose) was found to make 0.1% dietary fucoxanthin as effective at suppressing fat gain as double the dose.[633]

Fucoxanthin and fish oil may be synergistic in their anti-obesity effects. Further study is needed to confirm this relationship.

Interestingly, fucoxanthin can increase liver levels of DHA independent of fish oil consumption.[46]

18.6. Fenugreek

When a Fenugreek oil (formulated with 15% fish oil by weight) was given to diabetic rats at 5% of food intake, it resulted in a 51% decrease in blood glucose levels after a meal due to decrease the activity of carbohydrate digesting enzymes in the pancreas (46% reduction in α-amylase, 37% reduction in maltase) and plasma (52% α-amylase, 35% maltase).[634] The combination 5% group was slightly more potent than the 5% Fenugreek group and much more than the 5% fish oil group.

A protective effect on pancreatic beta-cells was also noted with this combination[634] as well as decreases in triglycerides attributed to the fish oil component. Said infusion also normalized the increase in ACE that diabetic rats experience.[634]

18.7. Taurine

Taurine is a sulfur-containing amino acid which is seen as anti-diabetic, it was investigated alongside Fish Oil fatty acids due to both being present in high amounts in seafood. The expected increases in body fat seen in diabetic mice subject to both taurine (at 4% of the diet) and fish oil was lesser with the combination than either nutrient alone, and the levels of insulin and glucose were lower with the combination than either molecule in isolation.[635]

Taurine potentially has additive benefits when taken with fish oil.

18.8. Statins

Among statin-treated patients, a more normalized ratio is still associated with slower rates of atheroma progression when compared to a high omega-6 ratio[636] and intervening to reduce the ratio via delivering dietary omega-3 fatty acids reduces cardiometabolic risk factors.[637] Due to the benefit of a normalized ratio even in statin patients and the high level of safety seen with fish oil during statin therapy,[638] they are thought to be worthy combinations.

Several studies have suggested that the combination of a statin drug (usually simvastatin) and omega-3 fatty acids (2-4g EPA+DHA) is complementary on improving HDL-C while it can reduce triglycerides (inherent property of fish oil) and appears to synergistically reduce LDL-C (which is notable, as fish oil alone may increase LDL-C).[271][299][639][638] Potential synergism or additive benefit has also been noted in regards to vascular function in diabetics[640] and this synergism appears to apply to lovastatin (via its nutraceutical form of Red Yeast Rice[641]).

The synergism between omega-3 fatty acids and statin drugs appeared to be similar in result to but either outperformed[642][643] or similar in potency[644] to a statin and fibrate combination therapy (rosuvastatin and fenofibrate).

Fish oil supplementation appears to be synergistic with statin drugs, in terms of improving cardiometabolic parameters, since both inherently lower triglyceride count and augment the low-density lipoprotein reduction of statin drugs. It is unclear at this time if this synergy has a role to play in people using statins and fibrates already.


Edit19. Safety and Toxicology

For the possible safety implications of lipid peroxidation from polyunsaturated fatty acids, please refer to the lipid peroxidation subsection of 'Interactions with Oxidation'.

19.1. Mercury in Fish and Fish-based Supplements

Although there are numerous toxins associated with fish consumption, mercury is the one at the forefront of concern due to its correlation with omega-3 intake in fish[645][217] and its adverse effects on child cognition when consumed by pregnant mothers, as mercury can pass the placental barrier[646] and reach the child; as assessed by umbilical cord exposure.[647] Other toxins do not have as strong a correlation in children, such as PCBs and Dioxins[648] and although a concern, are less of a concern relative to mercury.

Additionally, mercury just has an adverse pharmacokinetic profile. When fish is cooked, the methylmercury binds to meat proteins[649] and 95% of ingested mercury is absorbed within 2 days[650] where it persists in the body for 70-90 days.[651]

In some epidemiological research, high consumption of mercury is related to heart disease risk, mostly with whale meat[652] but related to the mercury intake itself.[653][654] The omega3s offer a protective effect though, and avoiding the highest sources of mercury reduces a lot of risk on cardiovascular disease.[655][656] Only the highest sources of mercury (shark and whale) seem to cause enough of an effect for significance to arise in this epidemiological research, although the effect of mercury per se may be dose dependent.

In food, one recent review noted that the safest fish in terms of "High omega3, low Mercury" were salmon, trout and shrimp.[654] They examined those three, as well as other common fish (cod, halibut, shark, three forms of tuna, mackeral, seabass, snapper, tilapia and swordfish) for mercury content. Their results were:

  • Mackeral, Cod, Trout, Catfish, Farm Raised and Canned Salmon, Shrimp, and Tilapia were all under 0.1mcg/g (0.044, 0.026, 0.020, 0.014-0.015, 0.027-0.076, 0.012, and 0.020; respectively)
  • Halibut and Canned Light Tuna crossed over 0.1mcg/g (0.069-0.160, 0.030-0.102)
  • Albacore Tuna, Snapper, Ahi Tuna, Chilean Sea Bass, Swordfish and Shark all were above 0.1mcg/g (0.148-0.259, 0.465, 0.291, 0.194, 0.293 and 0.541; respectively)

They[654] also averaged the omega-3 content of said species by doing a literature review of a few studies[657][658][659][660][661], their averages were:

  • Tilapia and Snapper had less than 0.2g/3oz (0.115 and 0.170)
  • Cod, Light Tuna, Catfish, and Shrimp had between 0.2-0.4g/3oz (0.204, 0.238, 0.260, 0.301)
  • Seabass and Swordfish had beteen 0.4-0.6g/3oz (0.417, 0.493)
  • Shark, Ahi Tuna, and Albacore Tuna had between 0.6-0.8g/3oz (0.711, 0.716, 0.732)
  • Halibut and Trout were between 0.8-1g/3oz (0.800, 0.818)
  • Salmon and Mackeral were above 1g/3oz (1.090-1.582, with farm raised salmon having more; canned mackeral at 1.251)

In supplements, fish oil capsules and cod liver oil seem to be relatively low in mercury. Although products will vary in concentrations (depending on the fish used), one study noted a range of 0.013ng/g-2.03ng/g Mercury and no detectable methylmercury in capsules and 0.233ng/g in cod liver oil.[7] A study conducted in the US looking at three (unnamed) brands noted values of 9.89ng/g, 38.8ng/g, and 123ng/g in one salmon oil product.[662]

A letter to the Editors in which independent testing was done[663] mentioned that many popular fish oil products sold in North America have below 0.1mcg/g; TwinLab, Kyolic, Nature's Way, Natrol, Health from the Sun, and Nordic were cited in this letter.[663]

Organochlorines and PCBs are at a minute level in supplementation, below the detection limit of many studies looking at them.[664] Some studies do note detection, however, and tend to be by far highest in predatory oils like shark oil (usually supplemented for the Squalene content).[6]

Supplements made from cod, sardines and mackerel (non-predatory cold water fish) are the safest in terms of mercury level. Krill Oil is another option, if a lower dose is used.

Farm-raised salmon, mackerel, cod, trout and shrimp are the best fish to eat if the goal is to get the most omega-3 fatty acids with the least amount of contaminants.

References

  1. Behan PO, Behan WM, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand. (1990)
  2. Stark KD, et al. Comparison of bloodstream fatty acid composition from African-American women at gestation, delivery, and postpartum. J Lipid Res. (2005)
  3. Kuriki K, et al. Plasma concentrations of (n-3) highly unsaturated fatty acids are good biomarkers of relative dietary fatty acid intakes: a cross-sectional study. J Nutr. (2003)
  4. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. (1979)
  5. Kaur G, et al. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog Lipid Res. (2011)
  6. Rawn DF, et al. Persistent organic pollutants in fish oil supplements on the Canadian market: polychlorinated biphenyls and organochlorine insecticides. J Food Sci. (2009)
  7. Smutna M, et al. Fish oil and cod liver as safe and healthy food supplements. Neuro Endocrinol Lett. (2009)
  8. Jordan RG. Prenatal omega-3 fatty acids: review and recommendations. J Midwifery Womens Health. (2010)
  9. Fernandes AR, et al. Dioxins and polychlorinated biphenyls (PCBs) in fish oil dietary supplements: occurrence and human exposure in the UK. Food Addit Contam. (2006)
  10. Bourdon JA, et al. Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of Omega-3 polyunsaturated fatty acid supplements: implications for daily intake of dioxins and PCBs. Food Chem Toxicol. (2010)
  11. Jacobs MN, et al. Organochlorine residues in fish oil dietary supplements: comparison with industrial grade oils. Chemosphere. (1998)
  12. Akutsu K, Tanaka Y, Hayakawa K. Occurrence of polybrominated diphenyl ethers and polychlorinated biphenyls in shark liver oil supplements. Food Addit Contam. (2006)
  13. Mahaffey KR. Methylmercury: a new look at the risks. Public Health Rep. (1999)
  14. Guéguen M, et al. Shellfish and residual chemical contaminants: hazards, monitoring, and health risk assessment along French coasts. Rev Environ Contam Toxicol. (2011)
  15. Choy CA, et al. The influence of depth on mercury levels in pelagic fishes and their prey. Proc Natl Acad Sci U S A. (2009)
  16. Maki KC, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. (2009)
  17. Schuchardt JP, et al. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. (2011)
  18. Dyerberg J, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. (2010)
  19. Neubronner J, et al. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J Clin Nutr. (2011)
  20. Hansen JB, et al. Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men. Eur J Clin Nutr. (1993)
  21. Doughman SD, Krupanidhi S, Sanjeevi CB. Omega-3 fatty acids for nutrition and medicine: considering microalgae oil as a vegetarian source of EPA and DHA. Curr Diabetes Rev. (2007)
  22. Adarme-Vega TC, et al. Microalgal biofactories: a promising approach towards sustainable omega-3 fatty acid production. Microb Cell Fact. (2012)
  23. Stamey JA, et al. Use of algae or algal oil rich in n-3 fatty acids as a feed supplement for dairy cattle. J Dairy Sci. (2012)
  24. Bernstein AM, et al. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr. (2012)
  25. Wu WH, et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr. (2006)
  26. Hadley KB, et al. Preclinical safety evaluation in rats using a highly purified ethyl ester of algal-docosahexaenoic acid. Food Chem Toxicol. (2010)
  27. Rosell MS, et al. Long-chain n-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. Am J Clin Nutr. (2005)
  28. Mayurasakorn K, et al. Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hypoxia and ischemia. Curr Opin Clin Nutr Metab Care. (2011)
  29. Igarashi M, et al. Upregulated liver conversion of alpha-linolenic acid to docosahexaenoic acid in rats on a 15 week n-3 PUFA-deficient diet. J Lipid Res. (2007)
  30. Jump DB, et al. Fatty acid regulation of hepatic gene transcription. J Nutr. (2005)
  31. Nakamura MT, Nara TY. Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot Essent Fatty Acids. (2003)
  32. Igarashi M, et al. Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain. J Lipid Res. (2007)
  33. Rao JS, et al. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry. (2007)
  34. Strokin M, Sergeeva M, Reiser G. Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. Br J Pharmacol. (2003)
  35. DeMar JC Jr, et al. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J Neurochem. (2004)
  36. Igarashi M, et al. Low liver conversion rate of alpha-linolenic to docosahexaenoic acid in awake rats on a high-docosahexaenoate-containing diet. J Lipid Res. (2006)
  37. Kinsella JE, Broughton KS, Whelan JW. Dietary unsaturated fatty acids: interactions and possible needs in relation to eicosanoid synthesis. J Nutr Biochem. (1990)
  38. Harnack K, Andersen G, Somoza V. Quantitation of alpha-linolenic acid elongation to eicosapentaenoic and docosahexaenoic acid as affected by the ratio of n6/n3 fatty acids. Nutr Metab (Lond). (2009)
  39. Tvrzicka E, et al. Fatty acids as biocompounds: their role in human metabolism, health and disease--a review. Part 1: classification, dietary sources and biological functions. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. (2011)
  40. Brenna JT, et al. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. (2009)
  41. Yamazaki K, et al. Comparison of the conversion rates of alpha-linolenic acid (18:3(n - 3)) and stearidonic acid (18:4(n - 3)) to longer polyunsaturated fatty acids in rats. Biochim Biophys Acta. (1992)
  42. Orr SK, et al. The fat-1 mouse has brain docosahexaenoic acid levels achievable through fish oil feeding. Neurochem Res. (2010)
  43. Das UN, Puskás LG. Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis. (2009)
  44. Smith BK, et al. A decreased n-6/n-3 ratio in the fat-1 mouse is associated with improved glucose tolerance. Appl Physiol Nutr Metab. (2010)
  45. Airanthi MK, et al. Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver. J Agric Food Chem. (2011)
  46. Tsukui T, et al. Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAy obese/diabetic mice. J Agric Food Chem. (2007)
  47. Anderson BM, Ma DW. Are all n-3 polyunsaturated fatty acids created equal. Lipids Health Dis. (2009)
  48. Dietary n-6 and n-3 Fatty Acid Balance and Cardiovascular Health
  49. Weisinger HS, et al. Retinal sensitivity loss in third-generation n-3 PUFA-deficient rats. Lipids. (2002)
  50. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys
  51. Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys
  52. Wheeler TG, Benolken RM, Anderson RE. Visual membranes: specificity of fatty acid precursors for the electrical response to illumination. Science. (1975)
  53. Bazan NG. Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res. (2003)
  54. Mori T, et al. Involvement of the arachidonic acid cascade in the hypersusceptibility to pentylenetetrazole-induced seizure during diazepam withdrawal. Biol Pharm Bull. (2012)
  55. Sun GY, et al. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. (2004)
  56. NMDA Receptor-Stimulated Release of Arachidonic Acid: Mechanisms for the Bazan Effect
  57. Walev I, et al. Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol. (2000)
  58. Sun GY, Hu ZY. Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Prog Brain Res. (1995)
  59. Björnsdottir H, et al. Inhibition of phospholipase A(2) abrogates intracellular processing of NADPH-oxidase derived reactive oxygen species in human neutrophils. Exp Cell Res. (2013)
  60. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. (2012)
  61. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood). (2008)
  62. Simopoulos AP. New products from the agri-food industry: the return of n-3 fatty acids into the food supply. Lipids. (1999)
  63. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. (1991)
  64. Sanders TA. Polyunsaturated fatty acids in the food chain in Europe. Am J Clin Nutr. (2000)
  65. Sugano M, Hirahara F. Polyunsaturated fatty acids in the food chain in Japan. Am J Clin Nutr. (2000)
  66. Pella D, et al. Effects of an Indo-Mediterranean diet on the omega-6/omega-3 ratio in patients at high risk of coronary artery disease: the Indian paradox. World Rev Nutr Diet. (2003)
  67. Eaton SB, et al. Dietary intake of long-chain polyunsaturated fatty acids during the paleolithic. World Rev Nutr Diet. (1998)
  68. Simopoulos AP. Overview of evolutionary aspects of omega 3 fatty acids in the diet. World Rev Nutr Diet. (1998)
  69. FATTY-ACID RATIOS IN FREE-LIVING AND DOMESTIC ANIMALS: Possible Implications for Atheroma
  70. Crawford MA, Gale MM, Woodford MH. Linoleic acid and linolenic acid elongation products in muscle tissue of Sncerus caffer and other ruminant species. Biochem J. (1969)
  71. RESOLVINS AND PROTECTINS
  72. Xu ZZ, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med. (2010)
  73. Serhan CN, et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. (2004)
  74. Mas E, et al. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem. (2012)
  75. Bannenberg GL. Resolvins: Current understanding and future potential in the control of inflammation. Curr Opin Drug Discov Devel. (2009)
  76. Recchiuti A. Resolvin D1 and its GPCRs in resolution circuits of inflammation. Prostaglandins Other Lipid Mediat. (2013)
  77. Xu MX, et al. Resolvin d1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther. (2013)
  78. Serhan CN, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. (2002)
  79. Asymmetric Acetylation of the Cyclooxygenase-2 Homodimer by Aspirin and Its Effects on the Oxygenation of Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids
  80. Rowlinson SW, et al. Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z, 13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(R)-hete. J Biol Chem. (2000)
  81. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A. (1983)
  82. Arita M, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. (2005)
  83. Meder W, et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. (2003)
  84. Cash JL, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med. (2008)
  85. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. (2005)
  86. Bazan NG, Birkle DL, Reddy TS. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun. (1984)
  87. Mukherjee PK, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. (2004)
  88. Marcheselli VL, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. (2003)
  89. Zhao Y, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One. (2011)
  90. Lukiw WJ, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. (2005)
  91. Sahlin C, et al. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci. (2007)
  92. Oksman M, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis. (2006)
  93. Lim GP, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. (2005)
  94. Kliewer SA, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. (1995)
  95. Forman BM, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. (1995)
  96. Krey G, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. (1997)
  97. Bundy GL, et al. Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues. J Med Chem. (1983)
  98. Mahmud I, et al. On the identification and biological properties of prostaglandin J2. Prostaglandins Leukot Med. (1984)
  99. Zulyniak MA, et al. Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. Metabolism. (2013)
  100. Vu-Dac N, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. (1995)
  101. Rosen ED, et al. Transcriptional regulation of adipogenesis. Genes Dev. (2000)
  102. Wang YX, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. (2003)
  103. Gani OA. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists. Cardiovasc Diabetol. (2008)
  104. Hasegawa H, et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production. Blood. (2007)
  105. Yu K, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. (1995)
  106. Xu HE, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. (1999)
  107. Hertz R, et al. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR). Eur J Biochem. (1996)
  108. Devchand PR, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. (1996)
  109. Lorente-Cebrián S, et al. Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin Sci (Lond). (2009)
  110. Xue B, et al. Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS One. (2012)
  111. Saha AK, et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. (2004)
  112. Wu Y, et al. Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo. PLoS One. (2012)
  113. Yan XP, et al. Effects of n-3 polyunsaturated fatty acids on rat livers after partial hepatectomy via LKB1-AMPK signaling pathway. Transplant Proc. (2011)
  114. Jing K, et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy. (2011)
  115. Gabler NK, et al. Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK. J Nutr Biochem. (2009)
  116. Yeung F, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. (2004)
  117. Yang Z, et al. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. (2010)
  118. Lorente-Cebrián S, et al. Eicosapentaenoic acid inhibits tumour necrosis factor-α-induced lipolysis in murine cultured adipocytes. J Nutr Biochem. (2012)
  119. Figueras M, et al. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring). (2011)
  120. González-Périz A, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. (2009)
  121. Jelenik T, et al. AMP-activated protein kinase α2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes. (2010)
  122. Maiuri MC, et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. (2009)
  123. Tasdemir E, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. (2008)
  124. Fredriksson R, et al. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett. (2003)
  125. Moore K, et al. Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: comparison with human GPR120 splice variants. Comp Biochem Physiol B Biochem Mol Biol. (2009)
  126. Oh DY, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. (2010)
  127. Lin DC, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. (2012)
  128. Burns RN, Moniri NH. Agonism with the omega-3 fatty acids alpha-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem Biophys Res Commun. (2010)
  129. Morishita M, et al. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release. (2008)
  130. Hirasawa A, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. (2005)
  131. Tanaka T, et al. Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol. (2008)
  132. Oh DY, Olefsky JM. Omega 3 fatty acids and GPR120. Cell Metab. (2012)
  133. Im DS. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res. (2012)
  134. Itoh Y, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. (2003)
  135. The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids
  136. Brown AJ, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. (2003)
  137. Wang J, et al. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. (2006)
  138. Augustin MA, et al. Intestinal passage of microencapsulated fish oil in rats following oral administration. Food Funct. (2011)
  139. Patten GS, et al. Site specific delivery of microencapsulated fish oil to the gastrointestinal tract of the rat. Dig Dis Sci. (2009)
  140. Marsen TA, et al. Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations. Prostaglandins Leukot Essent Fatty Acids. (1992)
  141. MOHRHAUER H, HOLMAN RT. ALTERATION OF THE FATTY ACID COMPOSITION OF BRAIN LIPIDS BY VARYING LEVELS OF DIETARY ESSENTIAL FATTY ACIDS. J Neurochem. (1963)
  142. Bourre JM, et al. Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. Biochim Biophys Acta. (1992)
  143. Moriguchi T, Harauma A, Salem N Jr. Plasticity of mouse brain docosahexaenoic Acid: modulation by diet and age. Lipids. (2013)
  144. Pawlosky RJ, Salem N Jr. Alcohol consumption in rhesus monkeys depletes tissues of polyunsaturated fatty acids and alters essential fatty acid metabolism. Alcohol Clin Exp Res. (1999)
  145. Pawlosky RJ, Bacher J, Salem N Jr. Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. Alcohol Clin Exp Res. (2001)
  146. Hamazaki T, et al. Anti-stress effects of DHA. Biofactors. (2000)
  147. Hamazaki T, et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest. (1996)
  148. Hamazaki T, et al. The effect of docosahexaenoic acid on aggression in elderly Thai subjects--a placebo-controlled double-blind study. Nutr Neurosci. (2002)
  149. Hamazaki T, et al. Docosahexaenoic acid does not affect aggression of normal volunteers under nonstressful conditions. A randomized, placebo-controlled, double-blind study. Lipids. (1998)
  150. Long SJ1, Benton D. A double-blind trial of the effect of docosahexaenoic acid and vitamin and mineral supplementation on aggression, impulsivity, and stress. Hum Psychopharmacol. (2013)
  151. Itomura M, et al. The effect of fish oil on physical aggression in schoolchildren--a randomized, double-blind, placebo-controlled trial. J Nutr Biochem. (2005)
  152. Raine A1, et al. Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial. J Child Psychol Psychiatry. (2014)
  153. Serum Phospholipid Docosahexaenonic Acid Is Associated with Cognitive Functioning during Middle Adulthood
  154. Gamoh S, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. (1999)
  155. Improved Working Memory but No Effect on Striatal Vesicular Monoamine Transporter Type 2 after Omega-3 Polyunsaturated Fatty Acid Supplementation
  156. Stonehouse W, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr. (2013)
  157. Fontani G, et al. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest. (2005)
  158. Chiu CC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. (2008)
  159. Stough C, et al. The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiol Aging. (2012)
  160. van de Rest O, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. (2008)
  161. Antypa N, et al. Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers. J Psychopharmacol. (2009)
  162. Jackson PA, et al. No effect of 12 weeks' supplementation with 1 g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18-35 years. Br J Nutr. (2012)
  163. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. (2009)
  164. Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry. (2008)
  165. Freeman MP, et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord. (2008)
  166. Doornbos B, et al. Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol Biol Psychiatry. (2009)
  167. Llorente AM, et al. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol. (2003)
  168. Su KP, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. (2008)
  169. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. (2002)
  170. Marangell LB, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. (2003)
  171. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. (2002)
  172. Lucas M, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr. (2009)
  173. Grenyer BF, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. (2007)
  174. Su KP, et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. (2003)
  175. Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA. Acta Neurol Scand. (1999)
  176. Keck PE Jr, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. (2006)
  177. Hirashima F, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. (2004)
  178. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. (2006)
  179. Stoll AL, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. (1999)
  180. Fenton WS, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. (2001)
  181. da Silva TM, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. (2008)
  182. Hallahan B, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry. (2007)
  183. Zanarini MC, Frankenburg FR. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. (2003)
  184. van de Rest O, et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. (2008)
  185. Rogers PJ, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr. (2008)
  186. Silvers KM, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. (2005)
  187. Fontani G, et al. Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with Omega-3 polyunsaturated fatty acids. Eur J Clin Invest. (2005)
  188. Jazayeri S, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. (2008)
  189. Laino CH, et al. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine. Eur J Pharmacol. (2010)
  190. Carlezon WA Jr, et al. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry. (2005)
  191. Kiecolt-Glaser JK, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun. (2012)
  192. van de Rest O, et al. Effect of fish oil supplementation on quality of life in a general population of older Dutch subjects: a randomized, double-blind, placebo-controlled trial. J Am Geriatr Soc. (2009)
  193. Chronic Sodium Valproate Selectively Decreases Protein Kinase C α and ε In Vitro
  194. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J. (1982)
  195. Evans SJ, et al. Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res. (2012)
  196. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev. (2008)
  197. Wurtman RJ, et al. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. (2000)
  198. Murphy BL, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. (2012)
  199. Eguchi R, et al. Fish oil consumption prevents glucose intolerance and hypercorticosteronemy in footshock-stressed rats. Lipids Health Dis. (2011)
  200. Hamazaki T, et al. Administration of docosahexaenoic acid influences behavior and plasma catecholamine levels at times of psychological stress. Lipids. (1999)
  201. Sawazaki S, et al. The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study. J Nutr Sci Vitaminol (Tokyo). (1999)
  202. Song C, et al. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res. (2003)
  203. Takeuchi T, Iwanaga M, Harada E. Possible regulatory mechanism of DHA-induced anti-stress reaction in rats. Brain Res. (2003)
  204. Hamazaki K, et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition. (2005)
  205. Ximenes da Silva A, et al. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J Neurochem. (2002)
  206. Pifferi F, et al. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J Nutr. (2005)
  207. Pifferi F, et al. n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukot Essent Fatty Acids. (2007)
  208. Pifferi F, et al. n-3 long-chain fatty acids and regulation of glucose transport in two models of rat brain endothelial cells. Neurochem Int. (2010)
  209. Tsukada H, et al. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys. Brain Res. (2000)
  210. Nugent S, et al. Brain and systemic glucose metabolism in the healthy elderly following fish oil supplementation. Prostaglandins Leukot Essent Fatty Acids. (2011)
  211. Katayama Y, et al. Effect of long-term administration of ethyl eicosapentate (EPA-E) on local cerebral blood flow and glucose utilization in stroke-prone spontaneously hypertensive rats (SHRSP). Brain Res. (1997)
  212. Steinbrink J, et al. Illuminating the BOLD signal: combined fMRI-fNIRS studies. Magn Reson Imaging. (2006)
  213. Jackson PA, et al. DHA-rich oil modulates the cerebral haemodynamic response to cognitive tasks in healthy young adults: a near IR spectroscopy pilot study. Br J Nutr. (2012)
  214. Jackson PA, et al. Docosahexaenoic acid-rich fish oil modulates the cerebral hemodynamic response to cognitive tasks in healthy young adults. Biol Psychol. (2012)
  215. Bouzan C, et al. A quantitative analysis of fish consumption and stroke risk. Am J Prev Med. (2005)
  216. He K, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke. (2004)
  217. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. (2006)
  218. Mozaffarian D, et al. Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch Intern Med. (2005)
  219. Yamagishi K, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. (2008)
  220. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. (2000)
  221. Salem N Jr, et al. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. (2001)
  222. N-3 Fatty Acid Rich Triglyceride Emulsions Are Neuroprotective after Cerebral Hypoxic-Ischemic Injury in Neonatal Mice
  223. Schaefer EJ, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. (2006)
  224. Huang TL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. (2005)
  225. Kalmijn S, et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. (2004)
  226. Morris MC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol. (2005)
  227. Samieri C, et al. Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology. (2012)
  228. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging
  229. Quinn JF, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. (2010)
  230. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. (2000)
  231. Xiang Z, et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. (2002)
  232. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity
  233. Strokin M, Sergeeva M, Reiser G. Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2. J Neurochem. (2007)
  234. de Wilde MC, et al. Docosahexaenoic acid reduces amyloid-β(1-42) secretion in human AβPP-transfected CHO-cells by mechanisms other than inflammation related to PGE₂. J Alzheimers Dis. (2010)
  235. Hashimoto M, et al. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr. (2005)
  236. Hashimoto M, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem. (2002)
  237. Hashimoto M, et al. Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol. (2006)
  238. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett. (2002)
  239. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. (2002)
  240. Calon F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. (2004)
  241. Wurtman RJ. Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. Metabolism. (2008)
  242. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. (2007)
  243. Freund-Levi Y, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. (2006)
  244. Freund-Levi Y, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry. (2008)
  245. Yurko-Mauro K, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. (2010)
  246. Dangour AD, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr. (2010)
  247. Arita M, et al. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem. (2006)
  248. Wittamer V, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. (2003)
  249. Zhuang ZY, et al. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci. (2004)
  250. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. (2007)
  251. de Grooth GJ, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res. (2004)
  252. Quinet E, et al. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest. (1991)
  253. Föger B, et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. (1996)
  254. Fusegawa Y, et al. Influence of dietary fatty acid composition on the relationship between CETP activity and plasma lipoproteins in monkeys. J Lipid Res. (2001)
  255. Sparks DL, et al. Relationship between cholesteryl ester transfer activity and high density lipoprotein composition in hyperlipidemic patients. Atherosclerosis. (1989)
  256. de Grooth GJ, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis. (2004)
  257. Kastelein J. What future for combination therapies. Int J Clin Pract Suppl. (2003)
  258. Barter PJ. Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler Suppl. (2002)
  259. Boberg M, et al. Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. (1992)
  260. Connor WE, et al. The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci. (1993)
  261. Goh YK, et al. Effect of omega 3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients. Diabetologia. (1997)
  262. de Silva PP, Davis PJ, Cheema SK. Hyperlipidaemic effect of fish oil in Bio F1B hamsters. Br J Nutr. (2004)
  263. Ishida T, et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: Participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids. (2013)
  264. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. (2011)
  265. Eslick GD, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. (2009)
  266. Stradling C, et al. The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. PLoS One. (2012)
  267. Pei J, et al. The effect of n-3 polyunsaturated fatty acids on plasma lipids and lipoproteins in patients with chronic renal failure--a meta-analysis of randomized controlled trials. J Ren Nutr. (2012)
  268. Hartweg J, et al. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol. (2009)
  269. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. (1997)
  270. Theobald HE, et al. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr. (2004)
  271. Davidson MH, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. (2007)
  272. Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. (2004)
  273. Kelley DS, et al. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. (2007)
  274. Maki KC, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. (2005)
  275. Geppert J, et al. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br J Nutr. (2006)
  276. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr. (1996)
  277. Agren JJ, et al. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr. (1996)
  278. Mori TA, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. (2000)
  279. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. (1999)
  280. Satoh N, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. (2007)
  281. Kurabayashi T, Okada M, Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. Obstet Gynecol. (2000)
  282. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. (2003)
  283. Grimsgaard S, et al. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. (1997)
  284. Nestel P, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. (2002)
  285. Woodman RJ, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr. (2002)
  286. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care. (2006)
  287. Hanwell HE, et al. Acute fish oil and soy isoflavone supplementation increase postprandial serum (n-3) polyunsaturated fatty acids and isoflavones but do not affect triacylglycerols or biomarkers of oxidative stress in overweight and obese hypertriglyceridemic men. J Nutr. (2009)
  288. Maki KC, et al. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids. (2011)
  289. Schirmer SH, et al. Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation. Atherosclerosis. (2012)
  290. Egert S, et al. Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr. (2009)
  291. Nestel PJ. Fish oil attenuates the cholesterol induced rise in lipoprotein cholesterol. Am J Clin Nutr. (1986)
  292. Illingworth DR, Harris WS, Connor WE. Inhibition of low density lipoprotein synthesis by dietary omega-3 fatty acids in humans. Arteriosclerosis. (1984)
  293. de Lorgeril M, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. (1994)
  294. Impact of n-3 fatty acids on endothelial function: results from human interventions studies
  295. Montori VM, et al. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care. (2000)
  296. Friedberg CE, et al. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care. (1998)
  297. MacLean CH, et al. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ). (2004)
  298. Hartweg J, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev. (2008)
  299. Maki KC, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. (2008)
  300. Luo J, et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care. (1998)
  301. Schectman G, Kaul S, Kissebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes. (1988)
  302. Giacco R, et al. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids. Nutr Metab Cardiovasc Dis. (2007)
  303. Egert S, et al. Effects of dietary alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on parameters of glucose metabolism in healthy volunteers. Ann Nutr Metab. (2008)
  304. Bortolotti M, Tappy L, Schneiter P. Fish oil supplementation does not alter energy efficiency in healthy males. Clin Nutr. (2007)
  305. Tsitouras PD, et al. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm Metab Res. (2008)
  306. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care. (2009)
  307. Ramel A, et al. Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults. Diabetologia. (2008)
  308. Rivellese AA, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care. (1996)
  309. Krebs JD, et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond). (2006)
  310. Browning LM, et al. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab. (2007)
  311. Treatment for 2 mo with n–3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
  312. Hendrich S. (n-3) Fatty Acids: Clinical Trials in People with Type 2 Diabetes. Adv Nutr. (2010)
  313. Haugaard SB, et al. Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. Clin Endocrinol {Oxf}. (2006)
  314. Faeh D, et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. (2005)
  315. Dekker MJ, et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. (2010)
  316. Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol. (2010)
  317. Sawada K, et al. Ameliorative effects of polyunsaturated fatty acids against palmitic acid-induced insulin resistance in L6 skeletal muscle cells. Lipids Health Dis. (2012)
  318. Huang T, et al. Plasma phospholipids n-3 polyunsaturated fatty acid is associated with metabolic syndrome. Mol Nutr Food Res. (2010)
  319. Lauretani F, et al. Omega-3 and renal function in older adults. Curr Pharm Des. (2009)
  320. Huang T, et al. Increased plasma n-3 polyunsaturated fatty acid is associated with improved insulin sensitivity in type 2 diabetes in China. Mol Nutr Food Res. (2010)
  321. Flachs P, et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia. (2005)
  322. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. (2004)
  323. Rufer AC, Thoma R, Hennig M. Structural insight into function and regulation of carnitine palmitoyltransferase. Cell Mol Life Sci. (2009)
  324. Nakatani T, et al. Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem. (2002)
  325. Tsuboyama-Kasaoka N, et al. Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice. Biochem Biophys Res Commun. (1999)
  326. Kunesová M, et al. The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women. Physiol Res. (2006)
  327. Couet C, et al. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes Relat Metab Disord. (1997)
  328. Kabir M, et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr. (2007)
  329. Neschen S, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes. (2006)
  330. Shirai N, Suzuki H. Effects of simultaneous intakes of fish oil and green tea extracts on plasma, glucose, insulin, C-peptide, and adiponectin and on liver lipid concentrations in mice fed low- and high-fat diets. Ann Nutr Metab. (2008)
  331. Gammelmark A, et al. Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects. Nutr Res. (2012)
  332. Flachs P, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. (2006)
  333. Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes. Obesity (Silver Spring). (2011)
  334. Rossi AS, et al. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol. (2005)
  335. Todoric J, et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia. (2006)
  336. Ma T, et al. Sucrose counteracts the anti-inflammatory effect of fish oil in adipose tissue and increases obesity development in mice. PLoS One. (2011)
  337. Baillie RA, et al. Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body fat deposition. Prostaglandins Leukot Essent Fatty Acids. (1999)
  338. Belzung F, Raclot T, Groscolas R. Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am J Physiol. (1993)
  339. Hainault I, et al. Fish oil in a high lard diet prevents obesity, hyperlipemia, and adipocyte insulin resistance in rats. Ann N Y Acad Sci. (1993)
  340. Parrish CC, Pathy DA, Angel A. Dietary fish oils limit adipose tissue hypertrophy in rats. Metabolism. (1990)
  341. Pérez-Matute P, et al. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr. (2007)
  342. Ruzickova J, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids. (2004)
  343. Huang XF, et al. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab. (2004)
  344. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev. (2009)
  345. Lorente-Cebrián S, et al. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes. J Physiol Biochem. (2006)
  346. Dietary Fatty Acids Influence the Activity and Metabolic Control of Mitochondrial Carnitine Palmitoyltransferase I in Rat Heart and Skeletal Muscle
  347. Mascaró C, et al. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem. (1998)
  348. Fish consumption and risk of stroke in man
  349. Iso H, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA. (2001)
  350. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors
  351. Warner JG Jr, et al. Combined effects of aerobic exercise and omega-3 fatty acids in hyperlipidemic persons. Med Sci Sports Exerc. (1989)
  352. Smith GI, et al. Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin Sci (Lond). (2011)
  353. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial
  354. An WS, et al. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol. (2009)
  355. Chen J, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. (2011)
  356. Yamazaki RK, et al. Low fish oil intake improves insulin sensitivity, lipid profile and muscle metabolism on insulin resistant MSG-obese rats. Lipids Health Dis. (2011)
  357. Lam YY, et al. Insulin-stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: the effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids. Biochim Biophys Acta. (2011)
  358. Delarue J, et al. Interaction of fish oil and a glucocorticoid on metabolic responses to an oral glucose load in healthy human subjects. Br J Nutr. (2006)
  359. Cha SH, et al. Chronic docosahexaenoic acid intake enhances expression of the gene for uncoupling protein 3 and affects pleiotropic mRNA levels in skeletal muscle of aged C57BL/6NJcl mice. J Nutr. (2001)
  360. Perez R, Cañón J, Dunner S. Genes associated with long-chain omega-3 fatty acids in bovine skeletal muscle. J Appl Genet. (2010)
  361. Hessvik NP, et al. Metabolic switching of human myotubes is improved by n-3 fatty acids. J Lipid Res. (2010)
  362. You JS, et al. Dietary fish oil alleviates soleus atrophy during immobilization in association with Akt signaling to p70s6k and E3 ubiquitin ligases in rats. Appl Physiol Nutr Metab. (2010)
  363. You JS, Park MN, Lee YS. Dietary fish oil inhibits the early stage of recovery of atrophied soleus muscle in rats via Akt-p70s6k signaling and PGF2α. J Nutr Biochem. (2010)
  364. Ryan AM, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. (2009)
  365. Read JA, et al. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer. (2007)
  366. Fearon KC, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. (2003)
  367. Tishinsky JM, et al. Fish oil prevents high saturated fat diet-induced impairments in adiponectin and insulin response in rodent soleus muscle. Am J Physiol Regul Integr Comp Physiol. (2011)
  368. Guebre-Egziabher F, et al. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur J Clin Nutr. (2008)
  369. Aas V, et al. Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells. J Lipid Res. (2006)
  370. Abbott SK, Else PL, Hulbert AJ. Membrane fatty acid composition of rat skeletal muscle is most responsive to the balance of dietary n-3 and n-6 PUFA. Br J Nutr. (2010)
  371. Haugaard SB, et al. Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. Lipids Health Dis. (2009)
  372. Jolly CA, et al. Dietary (n-3) polyunsaturated fatty acids suppress murine lymphoproliferation, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. J Nutr. (1997)
  373. Alnajjar A, et al. Effect of n-3 and n-6 polyunsaturated fatty acids on lymphocyte proliferation, interleukin production and phospholipid fatty acids composition in type 2 diabetic and healthy subjects in Jordan people. Prostaglandins Leukot Essent Fatty Acids. (2006)
  374. Endres S, et al. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol. (1993)
  375. Smith KA. The interleukin 2 receptor. Adv Immunol. (1988)
  376. Nedwin GE, et al. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. (1985)
  377. Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. (1988)
  378. Gorjão R, et al. Regulation of interleukin-2 signaling by fatty acids in human lymphocytes. J Lipid Res. (2007)
  379. Mathias S, et al. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science. (1993)
  380. Szamel M, Resch K. T-cell antigen receptor-induced signal-transduction pathways--activation and function of protein kinases C in T lymphocytes. Eur J Biochem. (1995)
  381. Thienprasert A, et al. Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial. J Pediatr. (2009)
  382. Denys A, Hichami A, Khan NA. Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase (ERK1/ERK2) signaling in human T cells. J Lipid Res. (2001)
  383. Denys A, Hichami A, Khan NA. Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase enzyme activity in human T-cells. Mol Cell Biochem. (2002)
  384. Denys A, et al. Docosahexaenoic acid modulates phorbol ester-induced activation of extracellular signal-regulated kinases 1 and 2 in NIH/3T3 cells. Lipids. (2001)
  385. Denys A, Hichami A, Khan NA. n-3 PUFAs modulate T-cell activation via protein kinase C-alpha and -epsilon and the NF-kappaB signaling pathway. J Lipid Res. (2005)
  386. Pot GK, et al. No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr. (2009)
  387. Krysiak R, Gdula-Dymek A, Okopien B. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia. Eur J Clin Pharmacol. (2011)
  388. Malekshahi Moghadam A, et al. Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Singapore Med J. (2012)
  389. Gray P, et al. Fish oil supplementation augments post-exercise immune function in young males. Brain Behav Immun. (2012)
  390. Gleeson M, et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. (2011)
  391. Andrade PM, et al. Effects of the fish-oil supplementation on the immune and inflammatory responses in elite swimmers. Prostaglandins Leukot Essent Fatty Acids. (2007)
  392. Ferrucci L, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. (2006)
  393. Fujioka S, et al. The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects--A randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol (Tokyo). (2006)
  394. Vega-López S, et al. Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism. (2004)
  395. Bloomer RJ, et al. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis. (2009)
  396. Rizza S, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. (2009)
  397. Dangardt F, et al. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis. (2010)
  398. Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. (1989)
  399. Tayyebi-Khosroshahi H, et al. Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-alfa in hemodialysis patients. Saudi J Kidney Dis Transpl. (2012)
  400. Deike E, et al. The Effects of Fish Oil Supplementation on Markers of Inflammation in Chronic Kidney Disease Patients. J Ren Nutr. (2012)
  401. Weaver KL, et al. Effect of dietary fatty acids on inflammatory gene expression in healthy humans. J Biol Chem. (2009)
  402. Reinders I, et al. Association of serum n-3 polyunsaturated fatty acids with C-reactive protein in men. Eur J Clin Nutr. (2012)
  403. Tomiyama H, et al. Relationships among the serum omega fatty acid levels, serum C-reactive protein levels and arterial stiffness/wave reflection in Japanese men. Atherosclerosis. (2011)
  404. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem. (2003)
  405. Poppitt SD, et al. Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke. (2009)
  406. Skulas-Ray AC, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. (2011)
  407. Kiecolt-Glaser JK, et al. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun. (2011)
  408. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology. Br J Clin Pharmacol. (2013)
  409. Kucia M, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. (2004)
  410. Schmidt EB, et al. Cod liver oil inhibits neutrophil and monocyte chemotaxis in healthy males. Atherosclerosis. (1989)
  411. Effect of dietary fish oil supplemented with different doses of vitamin e on neutrophil chemotaxis in healthy volunteers
  412. Schmidt EB, et al. Long-term supplementation with n-3 fatty acids, II: Effect on neutrophil and monocyte chemotaxis. Scand J Clin Lab Invest. (1992)
  413. Sperling RI, et al. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest. (1993)
  414. Hughes DA, Pinder AC. N-3 polyunsaturated fatty acids modulate the expression of functionally associated molecules on human monocytes and inhibit antigen-presentation in vitro. Clin Exp Immunol. (1997)
  415. Miles EA, Wallace FA, Calder PC. Dietary fish oil reduces intercellular adhesion molecule 1 and scavenger receptor expression on murine macrophages. Atherosclerosis. (2000)
  416. Sanderson P, Calder PC. Dietary fish oil diminishes lymphocyte adhesion to macrophage and endothelial cell monolayers. Immunology. (1998)
  417. Collie-Duguid ES, Wahle KW. Inhibitory effect of fish oil N-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun. (1996)
  418. De Caterina R, et al. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. (1994)
  419. Yamada H, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. (2008)
  420. Hughes DA, et al. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr. (1996)
  421. Luu NT, et al. Comparison of the pro-inflammatory potential of monocytes from healthy adults and those with peripheral arterial disease using an in vitro culture model. Atherosclerosis. (2007)
  422. Miles EA, et al. Influence of age and dietary fish oil on plasma soluble adhesion molecule concentrations. Clin Sci (Lond). (2001)
  423. Nielsen MS, et al. The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids. (2012)
  424. Stanke-Labesque F, et al. Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers. Br J Nutr. (2008)
  425. Lee TH, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. (1985)
  426. Elbim C, Lizard G. Flow cytometric investigation of neutrophil oxidative burst and apoptosis in physiological and pathological situations. Cytometry A. (2009)
  427. Omori K, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol. (2008)
  428. Bonatto SJ, et al. Fish oil supplementation improves neutrophil function during cancer chemotherapy. Lipids. (2012)
  429. Kim SK, Demetri GD. Chemotherapy and neutropenia. Hematol Oncol Clin North Am. (1996)
  430. Goldfarb Y, et al. Fish oil attenuates surgery-induced immunosuppression, limits post-operative metastatic dissemination and increases long-term recurrence-free survival in rodents inoculated with cancer cells. Clin Nutr. (2012)
  431. Thies F, et al. Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y. Am J Clin Nutr. (2001)
  432. Kelley DS, et al. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids. (1999)
  433. Miles EA, et al. Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males. Nutrition. (2006)
  434. Hall TJ, et al. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol. (1983)
  435. Interleukin-2 augments natural killer cell activity
  436. Harris DP, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. (2000)
  437. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol. (2008)
  438. Rockett BD, et al. n-3 PUFA improves fatty acid composition, prevents palmitate-induced apoptosis, and differentially modifies B cell cytokine secretion in vitro and ex vivo. J Lipid Res. (2010)
  439. Rockett BD, et al. Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function. J Lipid Res. (2012)
  440. Gurzell EA, et al. DHA-enriched fish oil targets B cell lipid microdomains and enhances ex vivo and in vivo B cell function. J Leukoc Biol. (2013)
  441. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. (1999)
  442. Chapkin RS, et al. Dietary n-3 PUFA affect TcR-mediated activation of purified murine T cells and accessory cell function in co-cultures. Clin Exp Immunol. (2002)
  443. Arrington JL, et al. Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation. Clin Exp Immunol. (2001)
  444. Ly LH, et al. Dietary eicosapentaenoic acid modulates CTLA-4 expression in murine CD4+ T-cells. Prostaglandins Leukot Essent Fatty Acids. (2006)
  445. Terada S, et al. Suppressive mechanisms of EPA on human T cell proliferation. Microbiol Immunol. (2001)
  446. Pompos LJ, Fritsche KL. Antigen-driven murine CD4+ T lymphocyte proliferation and interleukin-2 production are diminished by dietary (n-3) polyunsaturated fatty acids. J Nutr. (2002)
  447. Brix S, et al. CD4(+) T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by n-3 polyunsaturated fatty acids. Immunology. (2010)
  448. Thies F, et al. Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans. J Nutr. (2001)
  449. Kelley DS, et al. Dietary alpha-linolenic acid and immunocompetence in humans. Am J Clin Nutr. (1991)
  450. Peres CM, Otton R, Curi R. Modulation of lymphocyte proliferation by macrophages and macrophages loaded with arachidonic acid. Cell Biochem Funct. (2005)
  451. Nishiyama A, et al. Arachidonic acid-containing phosphatidylcholine inhibits lymphocyte proliferation and decreases interleukin-2 and interferon-gamma production from concanavalin A-stimulated rat lymphocytes. Biochim Biophys Acta. (2000)
  452. Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostaglandins Leukot Essent Fatty Acids. (1994)
  453. Fritsche KL, Johnston PV. Rapid autoxidation of fish oil in diets without added antioxidants. J Nutr. (1988)
  454. Yin H, et al. Identification of novel autoxidation products of the omega-3 fatty acid eicosapentaenoic acid in vitro and in vivo. J Biol Chem. (2007)
  455. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. (1991)
  456. Davis TA, et al. In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of fish oil omega-3 lipids on product distribution. J Am Chem Soc. (2006)
  457. Gonzalez MJ, et al. Lipid peroxidation products are elevated in fish oil diets even in the presence of added antioxidants. J Nutr. (1992)
  458. Seljeskog E, Hervig T, Mansoor MA. A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin Biochem. (2006)
  459. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem. (1966)
  460. Pryor WA, Porter NA. Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radic Biol Med. (1990)
  461. Niki E. Biomarkers of lipid peroxidation in clinical material. Biochim Biophys Acta. (2013)
  462. Tholstrup T, et al. A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men. J Nutr. (2004)
  463. Mori TA. Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep. (2004)
  464. Nälsén C, et al. Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr. (2006)
  465. Ottestad I, et al. Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial. Br J Nutr. (2011)
  466. Higdon JV, et al. Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes. Am J Clin Nutr. (2000)
  467. Ulven SM, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. (2011)
  468. Higdon JV, et al. Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate. J Lipid Res. (2001)
  469. Calzada C, et al. Subgram daily supplementation with docosahexaenoic acid protects low-density lipoproteins from oxidation in healthy men. Atherosclerosis. (2010)
  470. Oostenbrug GS, et al. Exercise performance, red blood cell deformability, and lipid peroxidation: effects of fish oil and vitamin E. J Appl Physiol. (1997)
  471. Sen CK, et al. Fish oil and vitamin E supplementation in oxidative stress at rest and after physical exercise. J Appl Physiol. (1997)
  472. Atalay M, et al. Vitamin E regulates changes in tissue antioxidants induced by fish oil and acute exercise. Med Sci Sports Exerc. (2000)
  473. Polavarapu R, et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology. (1998)
  474. Turner R, McLean CH, Silvers KM. Are the health benefits of fish oils limited by products of oxidation. Nutr Res Rev. (2006)
  475. Larsson SC, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. (2004)
  476. Kikugawa K, et al. Protective effect of supplementation of fish oil with high n-3 polyunsaturated fatty acids against oxidative stress-induced DNA damage of rat liver in vivo. J Agric Food Chem. (2003)
  477. Kikugawa K, et al. Effect of supplementation of n-3 polyunsaturated fatty acids on oxidative stress-induced DNA damage of rat hepatocytes. Biol Pharm Bull. (2003)
  478. Valko M, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. (2006)
  479. Schmitt D, et al. Toxicologic evaluation of DHA-rich algal oil: Genotoxicity, acute and subchronic toxicity in rats. Food Chem Toxicol. (2012)
  480. Umegaki K, et al. Docosahexaenoic acid supplementation-increased oxidative damage in bone marrow DNA in aged rats and its relation to antioxidant vitamins. Free Radic Res. (2001)
  481. Hilakivi-Clarke L, et al. Mechanisms mediating the effects of prepubertal (n-3) polyunsaturated fatty acid diet on breast cancer risk in rats. J Nutr. (2005)
  482. Kimura Y, et al. PUFAs in serum cholesterol ester and oxidative DNA damage in Japanese men and women. Am J Clin Nutr. (2012)
  483. Santos VC, et al. Effects of DHA-Rich Fish Oil Supplementation on Lymphocyte Function Before and After a Marathon Race. Int J Sport Nutr Exerc Metab. (2013)
  484. Shoji H, et al. Effect of docosahexaenoic acid and eicosapentaenoic acid supplementation on oxidative stress levels during pregnancy. Free Radic Res. (2006)
  485. Stonehouse W, et al. Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status. Br J Nutr. (2011)
  486. Ramel A, et al. Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction. Eur J Clin Nutr. (2010)
  487. Bourque C, et al. Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women. Metabolism. (2003)
  488. Kim YJ, Yokozawa T, Chung HY. Suppression of oxidative stress in aging NZB/NZW mice: effect of fish oil feeding on hepatic antioxidant status and guanidino compounds. Free Radic Res. (2005)
  489. Kim YJ, Yokozawa T, Chung HY. Effects of energy restriction and fish oil supplementation on renal guanidino levels and antioxidant defences in aged lupus-prone B/W mice. Br J Nutr. (2005)
  490. Pedersen BK, et al. Modulation of natural killer cell activity in peripheral blood by physical exercise. Scand J Immunol. (1988)
  491. Pedersen BK, et al. Indomethacin in vitro and in vivo abolishes post-exercise suppression of natural killer cell activity in peripheral blood. Int J Sports Med. (1990)
  492. Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation
  493. Mozurkewich EL, et al. The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial. Am J Obstet Gynecol. (2013)
  494. Makrides M, et al. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. (2010)
  495. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. (1998)
  496. Wang Y, et al. Dietary variables and glucose tolerance in pregnancy. Diabetes Care. (2000)
  497. Bo S, et al. Dietary fat and gestational hyperglycaemia. Diabetologia. (2001)
  498. Radesky JS, et al. Diet during early pregnancy and development of gestational diabetes. Paediatr Perinat Epidemiol. (2008)
  499. Zhou SJ, et al. Fish-oil supplementation in pregnancy does not reduce the risk of gestational diabetes or preeclampsia. Am J Clin Nutr. (2012)
  500. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol. (1988)
  501. Pedersen EB, et al. Prostaglandins, renin, aldosterone, and catecholamines in preeclampsia. Acta Med Scand Suppl. (1983)
  502. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. (2006)
  503. Olsen SF, et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet. (1992)
  504. Koletzko B, Larqué E, Demmelmair H. Placental transfer of long-chain polyunsaturated fatty acids (LC-PUFA). J Perinat Med. (2007)
  505. Hanebutt FL, et al. Long-chain polyunsaturated fatty acid (LC-PUFA) transfer across the placenta. Clin Nutr. (2008)
  506. Larqué E, et al. Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins. Am J Clin Nutr. (2006)
  507. Larque E, Demmelmair H, Koletzko B. Perinatal supply and metabolism of long-chain polyunsaturated fatty acids: importance for the early development of the nervous system. Ann N Y Acad Sci. (2002)
  508. Su HM, et al. Fetal baboons convert 18:3n-3 to 22:6n-3 in vivo. A stable isotope tracer study. J Lipid Res. (2001)
  509. Makrides M, et al. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr. (1994)
  510. Gould JF, Smithers LG, Makrides M. The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. (2013)
  511. Dunstan JA, et al. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. (2008)
  512. van Goor SA, et al. Supplementation of DHA but not DHA with arachidonic acid during pregnancy and lactation influences general movement quality in 12-week-old term infants. Br J Nutr. (2010)
  513. Tofail F, et al. Supplementation of fish-oil and soy-oil during pregnancy and psychomotor development of infants. J Health Popul Nutr. (2006)
  514. Helland IB, et al. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics. (2001)
  515. Innis SM, Friesen RW. Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants. Am J Clin Nutr. (2008)
  516. Decsi T, Campoy C, Koletzko B. Effect of N-3 polyunsaturated fatty acid supplementation in pregnancy: the Nuheal trial. Adv Exp Med Biol. (2005)
  517. Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial
  518. Impact of maternal docosahexaenoic acid (DHA) supplementation in the form of a functional food during pregnancy on infant neurodevelopment: A comparison of vision, memory, temperament and problem-solving abilities
  519. Farquharson J, et al. Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet. (1992)
  520. Jamieson EC, et al. Infant cerebellar gray and white matter fatty acids in relation to age and diet. Lipids. (1999)
  521. Lapillonne A, et al. Lipid needs of preterm infants: updated recommendations. J Pediatr. (2013)
  522. Straarup EM, et al. The stereospecific triacylglycerol structures and Fatty Acid profiles of human milk and infant formulas. J Pediatr Gastroenterol Nutr. (2006)
  523. Makrides M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr. (1996)
  524. Brenna JT, et al. Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. Am J Clin Nutr. (2007)
  525. Jensen CL, Lapillonne A. Docosahexaenoic acid and lactation. Prostaglandins Leukot Essent Fatty Acids. (2009)
  526. Francois CA, et al. Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am J Clin Nutr. (2003)
  527. Urwin HJ, et al. Salmon consumption during pregnancy alters fatty acid composition and secretory IgA concentration in human breast milk. J Nutr. (2012)
  528. Dunstan JA, et al. The effects of fish oil supplementation in pregnancy on breast milk fatty acid composition over the course of lactation: a randomized controlled trial. Pediatr Res. (2007)
  529. Imhoff-Kunsch B, et al. Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women. J Nutr. (2011)
  530. Helland IB, et al. Fatty acid composition in maternal milk and plasma during supplementation with cod liver oil. Eur J Clin Nutr. (1998)
  531. Boris J, et al. A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk. Lipids. (2004)
  532. The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n–3 fatty acid intake, and marine n–3 fatty acid status in maternal and umbilical cord blood
  533. Makrides M, et al. Changes in the polyunsaturated fatty acids of breast milk from mothers of full-term infants over 30 wk of lactation. Am J Clin Nutr. (1995)
  534. Moltó-Puigmartí C, et al. Differences in fat content and fatty acid proportions among colostrum, transitional, and mature milk from women delivering very preterm, preterm, and term infants. Clin Nutr. (2011)
  535. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. (2005)
  536. Futterman S, Kupfer C. The fatty acid composition of the retinal vasculature of normal and diabetic human eyes. Invest Ophthalmol. (1968)
  537. Tikhonenko M, et al. Remodeling of retinal Fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes. (2010)
  538. Decsi T, et al. Polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of diabetic children. Prostaglandins Leukot Essent Fatty Acids. (2002)
  539. Tikhonenko M, et al. N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. PLoS One. (2013)
  540. Opreanu M, et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes. (2011)
  541. Connor KM, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. (2007)
  542. Kang JX, et al. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature. (2004)
  543. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. (2000)
  544. McDaniel ML, et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med. (1996)
  545. Luo P, Wang MH. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat. (2011)
  546. Tran PO, Gleason CE, Robertson RP. Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function. Diabetes. (2002)
  547. Robertson RP. Arachidonic acid metabolite regulation of insulin secretion. Diabetes Metab Rev. (1986)
  548. Fujita H, et al. Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice. Biochem Biophys Res Commun. (2007)
  549. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes. (1998)
  550. Tran PO, et al. Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1beta. J Biol Chem. (1999)
  551. Persaud SJ, et al. The role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans. Diabetes. (2007)
  552. Oshima H, Taketo MM, Oshima M. Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem. (2006)
  553. Dobrian AD, et al. Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res. (2011)
  554. Weaver JR, et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endocrinol. (2012)
  555. Metz SA, Murphy RC, Fujimoto W. Effects on glucose-induced insulin secretion of lipoxygenase-derived metabolites of arachidonic acid. Diabetes. (1984)
  556. Ma K, et al. 12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets. J Clin Endocrinol Metab. (2010)
  557. Wei D, et al. Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes. (2010)
  558. Bellenger J, et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes. (2011)
  559. Wong CY, et al. Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med. (2010)
  560. Garman JH, et al. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol. (2009)
  561. Logan JL, Benson B, Lee SM. Dietary fish oil enhances renal hypertrophy in experimental diabetes. Diabetes Res Clin Pract. (1990)
  562. Hagiwara S, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant. (2006)
  563. Shapiro H, et al. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol. (2011)
  564. Hakim IA, Harris RB, Ritenbaugh C. Fat intake and risk of squamous cell carcinoma of the skin. Nutr Cancer. (2000)
  565. Kune GA, et al. Diet, alcohol, smoking, serum beta-carotene, and vitamin A in male nonmelanocytic skin cancer patients and controls. Nutr Cancer. (1992)
  566. Wallingford SC, et al. Intake of omega-3 and omega-6 fatty acids and risk of basal and squamous cell carcinomas of the skin: a longitudinal community-based study in Australian adults. Nutr Cancer. (2012)
  567. Fischer MA, Black HS. Modification of membrane composition, eicosanoid metabolism, and immunoresponsiveness by dietary omega-3 and omega-6 fatty acid sources, modulators of ultraviolet-carcinogenesis. Photochem Photobiol. (1991)
  568. Pilkington SM, et al. Randomized controlled trial of oral omega-3 PUFA in solar-simulated radiation-induced suppression of human cutaneous immune responses. Am J Clin Nutr. (2013)
  569. Lou YR, et al. Effects of high-fat diets rich in either omega-3 or omega-6 fatty acids on UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis. (2011)
  570. Black HS, et al. Influence of dietary omega-6, -3 fatty acid sources on the initiation and promotion stages of photocarcinogenesis. Photochem Photobiol. (1992)
  571. Orengo IF, et al. Influence of dietary menhaden oil upon carcinogenesis and various cutaneous responses to ultraviolet radiation. Photochem Photobiol. (1989)
  572. Ziboh VA, Miller CC. Essential fatty acids and polyunsaturated fatty acids: significance in cutaneous biology. Annu Rev Nutr. (1990)
  573. Reeve VE, Bosnic M, Boehm-Wilcox C. Dependence of photocarcinogenesis and photoimmunosuppression in the hairless mouse on dietary polyunsaturated fat. Cancer Lett. (1996)
  574. Fukui M, et al. EPA, an omega-3 fatty acid, induces apoptosis in human pancreatic cancer cells: role of ROS accumulation, caspase-8 activation, and autophagy induction. J Cell Biochem. (2013)
  575. Wright SA, et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. (2008)
  576. Duffy EM, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol. (2004)
  577. Ilowite NT, et al. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol. (1995)
  578. Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest. (1981)
  579. Robinson DR, et al. The protective effect of dietary fish oil on murine lupus. Prostaglandins. (1985)
  580. Clark WF, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int. (1993)
  581. Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. A double-blind, crossover study. Scand J Rheumatol. (1990)
  582. Walton AJ, et al. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis. (1991)
  583. Rhodes LE, et al. Dietary fish-oil supplementation in humans reduces UVB-erythemal sensitivity but increases epidermal lipid peroxidation. J Invest Dermatol. (1994)
  584. Rhodes LE, et al. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis. (2003)
  585. Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice
  586. Damian DL, Barnetson RS, Halliday GM. Effects of low-dose ultraviolet radiation on in vivo human cutaneous recall responses. Australas J Dermatol. (2001)
  587. Sivapirabu G, et al. Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol. (2009)
  588. Noonan FP, De Fabo EC, Kripke ML. Suppression of contact hypersensitivity by UV radiation and its relationship to UV-induced suppression of tumor immunity. Photochem Photobiol. (1981)
  589. Theilla M, et al. A diet enriched in eicosapentanoic acid, gamma-linolenic acid and antioxidants in the prevention of new pressure ulcer formation in critically ill patients with acute lung injury: A randomized, prospective, controlled study. Clin Nutr. (2007)
  590. Singer P, et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med. (2006)
  591. Theilla M, et al. Enteral n-3 fatty acids and micronutrients enhance percentage of positive neutrophil and lymphocyte adhesion molecules: a potential mediator of pressure ulcer healing in critically ill patients. Br J Nutr. (2012)
  592. Theilla M, et al. Impact of a nutritional formula enriched in fish oil and micronutrients on pressure ulcers in critical care patients. Am J Crit Care. (2012)
  593. Fish-oil-rich diet lowers bedsore symptoms by 20-25%
  594. Colombe L, et al. Prostaglandin metabolism in human hair follicle. Exp Dermatol. (2007)
  595. Yamamoto K, et al. Hair follicular expression and function of group X secreted phospholipase A2 in mouse skin. J Biol Chem. (2011)
  596. Torii E, et al. Expression of prostaglandin E(2) receptor subtypes in mouse hair follicles. Biochem Biophys Res Commun. (2002)
  597. Müller-Decker K, et al. Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression. J Invest Dermatol. (2003)
  598. Roenigk HH Jr. New topical agents for hair growth. Clin Dermatol. (1988)
  599. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. (2002)
  600. Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. (2005)
  601. Neufang G, et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A. (2001)
  602. Bol DK, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. (2002)
  603. Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. (2008)
  604. Bauman DR, Steckelbroeck S, Penning TM. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. (2004)
  605. Chen W, et al. Human sebocytes express prostaglandin E2 receptors EP2 and EP4 but treatment with prostaglandin E2 does not affect testosterone production. Br J Dermatol. (2009)
  606. Zhu H, et al. Expression and regulation of lipocalin-type prostaglandin d synthase in rat testis and epididymis. Biol Reprod. (2004)
  607. Treister NS, et al. Influence of androgens on gene expression in the BALB/c mouse submandibular gland. J Dent Res. (2005)
  608. Garza LA, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. (2012)
  609. Obata T, et al. Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells. Clin Exp Allergy. (1999)
  610. Tanaka Y, Otsuji A, Amano F. Suppression of prostaglandin synthesis by arachidonic acid or eicosapentaenoic acid in a macrophage-like cell line, RAW 264.7, treated with LPS. Biol Pharm Bull. (1999)
  611. Kirby NA, et al. Skin surface lipids and skin and hair coat condition in dogs fed increased total fat diets containing polyunsaturated fatty acids. J Anim Physiol Anim Nutr (Berl). (2009)
  612. Rees CA, et al. Effects of dietary flax seed and sunflower seed supplementation on normal canine serum polyunsaturated fatty acids and skin and hair coat condition scores. Vet Dermatol. (2001)
  613. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res. (1985)
  614. Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev. (2006)
  615. Ross BM, et al. Phospholipid biosynthetic enzymes in human brain. Lipids. (1997)
  616. Wurtman RJ, Cansev M, Ulus IH. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging. (2009)
  617. Wurtman RJ, et al. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. (2006)
  618. Damsgaard CT, et al. Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J Nutr. (2008)
  619. Sofi F, et al. The atherosclerotic risk profile is affected differently by fish flesh with a similar EPA and DHA content but different n-6/n-3 ratio. Asia Pac J Clin Nutr. (2013)
  620. Damsgaard CT, Frøkiaer H, Lauritzen L. The effects of fish oil and high or low linoleic acid intake on fatty acid composition of human peripheral blood mononuclear cells. Br J Nutr. (2008)
  621. Otton R, et al. Combined fish oil and astaxanthin supplementation modulates rat lymphocyte function. Eur J Nutr. (2012)
  622. Bolin AP, et al. Astaxanthin prevents in vitro auto-oxidative injury in human lymphocytes. Cell Biol Toxicol. (2010)
  623. Pompéia C, et al. Effect of fatty acids on leukocyte function. Braz J Med Biol Res. (2000)
  624. Altenburg JD, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer. (2011)
  625. Saw CL, Huang Y, Kong AN. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. (2010)
  626. Jia Q, et al. Dietary fish oil and curcumin combine to modulate colonic cytokinetics and gene expression in dextran sodium sulphate-treated mice. Br J Nutr. (2011)
  627. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. (2009)
  628. Nagappan G, Lu B. Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. Trends Neurosci. (2005)
  629. Suzuki H, et al. Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet. Mech Ageing Dev. (1998)
  630. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience. (2008)
  631. Wu A, Ying Z, Gomez-Pinilla F. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol. (2006)
  632. Gomez-Pinilla F. Collaborative effects of diet and exercise on cognitive enhancement. Nutr Health. (2011)
  633. Maeda H, et al. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem. (2007)
  634. Hamden K, et al. Inhibitory potential of omega-3 fatty and fenugreek essential oil on key enzymes of carbohydrate-digestion and hypertension in diabetes rats. Lipids Health Dis. (2011)
  635. Mikami N, Hosokawa M, Miyashita K. Dietary combination of fish oil and taurine decreases fat accumulation and ameliorates blood glucose levels in type 2 diabetic/obese KK-A(y) mice. J Food Sci. (2012)
  636. Nozue T, et al. Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol. (2013)
  637. Lee SP, et al. Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. Br J Nutr. (2012)
  638. Ballantyne CM, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. (2012)
  639. Vecka M, et al. N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuro Endocrinol Lett. (2012)
  640. Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. (2012)
  641. Becker DJ, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. (2008)
  642. Agouridis AP, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. (2011)
  643. Agouridis AP, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. (2012)
  644. Agouridis AP, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. (2011)
  645. Tsuji M, et al. Relationship between RBC mercury levels and serum n3 polyunsaturated fatty acid concentrations among Japanese men and women. J Environ Public Health. (2012)
  646. Boadi WY, et al. In vitro effect of mercury on enzyme activities and its accumulation in the first-trimester human placenta. Environ Res. (1992)
  647. Grandjean P, et al. Impact of maternal seafood diet on fetal exposure to mercury, selenium, and lead. Arch Environ Health. (1992)
  648. Huang MC, et al. Placental docosahexaenoic and arachidonic acids correlate weakly with placental polychlorinated dibenzofurans (PCDF) and are uncorrelated with polychlorinated dibenzo-p-dioxins (PCDD) or polychlorinated biphenyls (PCB) at delivery: a pilot study. Food Chem Toxicol. (2011)
  649. Domingo JL, et al. Benefits and risks of fish consumption Part I. A quantitative analysis of the intake of omega-3 fatty acids and chemical contaminants. Toxicology. (2007)
  650. Hightower JM, Moore D. Mercury levels in high-end consumers of fish. Environ Health Perspect. (2003)
  651. Health benefits and potential risks related to consumption of fish or fish oil
  652. Choi AL, et al. Methylmercury exposure and adverse cardiovascular effects in Faroese whaling men. Environ Health Perspect. (2009)
  653. Mercury as a risk factor for cardiovascular diseases
  654. Smith KL, Guentzel JL. Mercury concentrations and omega-3 fatty acids in fish and shrimp: Preferential consumption for maximum health benefits. Mar Pollut Bull. (2010)
  655. Mozaffarian D, et al. Mercury exposure and risk of cardiovascular disease in two U.S. cohorts. N Engl J Med. (2011)
  656. Yoshizawa K, et al. Mercury and the risk of coronary heart disease in men. N Engl J Med. (2002)
  657. Mahaffey KR, Clickner RP, Jeffries RA. Methylmercury and omega-3 fatty acids: co-occurrence of dietary sources with emphasis on fish and shellfish. Environ Res. (2008)
  658. Harris WS, Kris-Etherton PM, Harris KA. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. (2008)
  659. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol. (2006)
  660. Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci. (1993)
  661. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
  662. Levine KE, et al. Determination of mercury in an assortment of dietary supplements using an inexpensive combustion atomic absorption spectrometry technique. J Autom Methods Manag Chem. (2005)
  663. Schaller JL. Mercury and fish oil supplements. MedGenMed. (2001)
  664. Melanson SF, et al. Measurement of organochlorines in commercial over-the-counter fish oil preparations: implications for dietary and therapeutic recommendations for omega-3 fatty acids and a review of the literature. Arch Pathol Lab Med. (2005)
  665. Wang C, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. (2006)
  666. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3). Int J Vitam Nutr Res. (1998)
  667. Brenna JT. Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care. (2002)
  668. Fokkema MR, et al. Short-term supplementation of low-dose gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. Prostaglandins Leukot Essent Fatty Acids. (2000)
  669. Byleveld PM, et al. Fish oil feeding delays influenza virus clearance and impairs production of interferon-gamma and virus-specific immunoglobulin A in the lungs of mice. J Nutr. (1999)
  670. Schwerbrock NM, et al. Fish oil-fed mice have impaired resistance to influenza infection. J Nutr. (2009)
  671. Byleveld M, et al. Fish oil feeding enhances lymphocyte proliferation but impairs virus-specific T lymphocyte cytotoxicity in mice following challenge with influenza virus. Clin Exp Immunol. (2000)
  672. Lenn J, et al. The effects of fish oil and isoflavones on delayed onset muscle soreness. Med Sci Sports Exerc. (2002)
  673. Tartibian B, Maleki BH, Abbasi A. The effects of ingestion of omega-3 fatty acids on perceived pain and external symptoms of delayed onset muscle soreness in untrained men. Clin J Sport Med. (2009)
  674. Simão AN, et al. Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide. Br J Nutr. (2012)
  675. Geelen A, et al. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr. (2004)
  676. Madsen T, et al. The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Br J Nutr. (2003)
  677. Yusof HM, Miles EA, Calder P. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids. (2008)
  678. Cazzola R, et al. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis. (2007)
  679. Michaeli B, et al. Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. Clin Nutr. (2007)
  680. Pittet YK, et al. Blunting the response to endotoxin in healthy subjects: effects of various doses of intravenous fish oil. Intensive Care Med. (2010)
  681. Paulo MC, et al. Influence of n-3 polyunsaturated fatty acids on soluble cellular adhesion molecules as biomarkers of cardiovascular risk in young healthy subjects. Nutr Metab Cardiovasc Dis. (2008)
  682. Oliveira JM, Rondó PH. Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. HIV Clin Trials. (2011)
  683. Campbell F, et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiolog. (2012)
  684. Oelrich B, Dewell A, Gardner CD. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. Nutr Metab Cardiovasc Dis. (2011)
  685. Mozaffarian D, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. (2005)
  686. Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr. (2011)
  687. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. (2011)
  688. Sublette ME, et al. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. (2011)
  689. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. (2012)
  690. Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician. (2011)
  691. Phelan N, et al. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial. Am J Clin Nutr. (2011)
  692. Olendzki BC, et al. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evid Based Complement Alternat Med. (2011)
  693. Sanders TA, et al. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr. (2011)
  694. Serebruany VL, et al. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology. (2011)
  695. Vargas ML, et al. Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome. Metabolism. (2011)
  696. Nobili V, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. (2011)
  697. Maki KC, et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol. (2011)
  698. Filaire E, et al. Effect of 6 Weeks of n-3 fatty-acid supplementation on oxidative stress in Judo athletes. Int J Sport Nutr Exerc Metab. (2010)
  699. Fakhrzadeh H, et al. The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial. Int J Vitam Nutr Res. (2010)
  700. Dawczynski C, et al. n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study. Clin Nutr. (2010)
  701. Bays HE, et al. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Postgrad Med. (2009)
  702. Thusgaard M, et al. Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. Scand J Infect Dis. (2009)
  703. Stevens L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. (2003)
  704. Gustafsson PA, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. (2010)
  705. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr. (2007)
  706. Bélanger SA, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr Child Health. (2009)
  707. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry. (2002)
  708. Voigt RG, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. (2001)
  709. Pooya Sh, et al. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis. (2010)
  710. Shidfar F, et al. Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients. East Mediterr Health J. (2008)
  711. Munro IA, Garg ML. Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. Br J Nutr. (2012)
  712. Ramel A, et al. Moderate consumption of fatty fish reduces diastolic blood pressure in overweight and obese European young adults during energy restriction. Nutrition. (2010)
  713. Mackay I, et al. Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease. Atherosclerosis. (2012)
  714. Finocchiaro C, et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. (2011)
  715. Kooshki A, et al. Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients. Ann Nutr Metab. (2011)
  716. Schuchardt JP, et al. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids. (2011)
  717. Akinkuolie AO, et al. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. (2011)
  718. Annuzzi G, et al. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. Atherosclerosis. (1991)
  719. Axelrod L, et al. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care. (1994)
  720. Borkman M, et al. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes. (1989)
  721. Hendra TJ, et al. Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care. (1990)
  722. Pelikánová T, et al. Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. Ann N Y Acad Sci. (1993)
  723. Morgan WA, Raskin P, Rosenstock J. A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. Diabetes Care. (1995)
  724. McManus RM, et al. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes. Diabetes Care. (1996)

(Common misspellings for Fish Oil include fsh oil, omga, omega, omiga, omaga)

(Common phrases used by users for this page include what is fish oil?, omega 3 and immunosuppression, fish oils contents, fish oil supplement detail, examine.com glycerol, does fish oil increase memory attriction)

(Users who contributed to this page include shrillthrill, , , blaabjerg, dbarvinok, thegoldenavatar, Damien, schuman0)